

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1656

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:12:48 ON 28 DEC 2009

=> File Medline Scisearch EMBASE Biosis Caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'MEDLINE' ENTERED AT 17:12:57 ON 28 DEC 2009

FILE 'SCISEARCH' ENTERED AT 17:12:57 ON 28 DEC 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:12:57 ON 28 DEC 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:12:57 ON 28 DEC 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 17:12:57 ON 28 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> S (protease variant) (P) (unexpected substrate)

L1 0 (PROTEASE VARIANT) (P) (UNEXPECTED SUBSTRATE)

=> S (protease variant) (P) (unexpected cleavage)

L2 0 (PROTEASE VARIANT) (P) (UNEXPECTED CLEAVAGE)

=> S (protease variant) (P) (unexpected (3A) cleavage)

L3 0 (PROTEASE VARIANT) (P) (UNEXPECTED (3A) CLEAVAGE)

=> S (protease variant) (P) (unexpected (3A) substrate)

L4 0 (PROTEASE VARIANT) (P) (UNEXPECTED (3A) SUBSTRATE)

=> S (protease variant) (P) (unpredictable (3A) substrate)

L5 0 (PROTEASE VARIANT) (P) (UNPREDICTABLE (3A) SUBSTRATE)

=> S (protease variant) (P) (unpredictable (3A) cleavage)

L6 0 (PROTEASE VARIANT) (P) (UNPREDICTABLE (3A) CLEAVAGE)

=> S (protease or proteinase or peptidase) (3A) (variant or mutant or mutated or mutation or mutating or mutagenesis or substitution or substitute or substituted or substituting or replace or replaced or replacing or replacement or exchange or exchanged or exchanging)

L7 8630 (PROTEASE OR PROTEINASE OR PEPTIDASE) (3A) (VARIANT OR MUTANT OR MUTATED OR MUTATION OR MUTATING OR MUTAGENESIS OR SUBSTITUTION OR SUBSTITUTE OR SUBSTITUTED OR SUBSTITUTING OR REPLACE OR REPLACED OR REPLACING OR REPLACEMENT OR EXCHANGE OR EXCHANGED OR EXCHANGING)

=> S (protease or proteinase or peptidase) (4A) (unexpected or unexpectedly or unpredictable (2A) cleavage or cleaved or cleaving or cleaves)

L8 12942 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (UNEXPECTED OR UNEXPECTEDLY OR UNPREDICTABLE (2A) CLEAVAGE OR CLEAVED OR CLEAVING OR CLEAVES)

=> s 17 and 18  
L9 228 L7 AND L8

=> s 17 (P) 18  
L10 161 L7 (P) L8

=> duplicate  
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove  
ENTER L# LIST OR (END):  
ENTER L# LIST OR (END):110  
DUPLICATE PREFERENCE IS 'MEDLINE, SCISEARCH, EMBASE, BIOSIS, CAPLUS'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L10  
L11 51 DUPLICATE REMOVE L10 (110 DUPLICATES REMOVED)

=> d 111 1-51 bib ab

L11 ANSWER 1 OF 51 MEDLINE on STN DUPLICATE 1  
AN 2009671757 IN-PROCESS  
DN PubMed ID: 19556225  
TI Insights into the enzyme-substrate interaction in the norovirus 3C-like protease.  
AU Someya Yuichi; Takeda Naokazu  
CS Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan.. someya@nih.go.jp  
SO Journal of biochemistry, (2009 Oct) Vol. 146, No. 4, pp. 509-21.  
Electronic Publication: 2009-06-24.  
Journal code: 0376600. E-ISSN: 1756-2651. L-ISSN: 0021-924X.  
CY England: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals  
ED Entered STN: 8 Oct 2009  
Last Updated on STN: 16 Dec 2009  
AB The Glu54 residue of the norovirus 3C-like protease was implicated in proteolysis as a third-member carboxylate of the catalytic triad. The E54L mutant protease cleaved the sequence (133)LSFE/AP between the 3B and 3C regions of norovirus polyprotein, but did not cleave the sequence (198)ATSE/GK between the 3A and 3B. The 3BC junction mutation (3B-L133A or 3B-F135S) hampered the cleavage by the E54L protease, whereas the 3AB junction mutation (3A-A198L, S200F) allowed the E54L protease to digest. These results indicate that the E54L mutant protease is a substrate-specificity mutant and requires large hydrophobic amino acid residues at both P4 and P2 positions of the substrate. It was notable that the 3A-S200F P2 position mutation caused tight interaction between the wild-type protease and the C-terminus of the 3A protein, hence a decreased release rate of the product from the enzyme. This tight binding was dependent on the hydrophobicity of amino acid residues introduced at position 200 of the 3A region and was affected by the mutation in the bII-cII loop of the protease or the mutation of position 198 of 3A corresponding to the P4 position of the substrate. These results suggest that the protease and the substrate sense each other in the process of the proteolysis, being supported by crystal structures.

L11 ANSWER 2 OF 51 MEDLINE on STN DUPLICATE 2  
AN 2008333385 MEDLINE  
DN PubMed ID: 18400852  
TI Poliovirus 2A(Pro) increases viral mRNA and polysome stability

coordinately in time with cleavage of eIF4G.  
 AU Kempf Brian J; Barton David J  
 CS Department of Microbiology, University of Colorado Denver, School of  
 Medicine, 12800 East 19th Ave., Aurora, CO 80045, USA.  
 NC AI42189 (United States NIAID NIH HHS)  
 T32 AI07537 (United States NIAID NIH HHS)  
 SO Journal of virology, (2008 Jun) Vol. 82, No. 12, pp. 5847-59. Electronic  
 Publication: 2008-04-09.  
 Journal code: 0113724. E-ISSN: 1098-5514.  
 Report No.: NLM-PMC2395153.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 LA English  
 FS Priority Journals  
 EM 200808  
 ED Entered STN: 24 May 2008  
 Last Updated on STN: 13 Aug 2008  
 Entered Medline: 12 Aug 2008  
 AB Poliovirus (PV) 2A protease (2A(Pro)) cleaves  
 eukaryotic initiation factors 4GI and 4GII (eIF4GI and eIF4GII) within  
 virus-infected cells, effectively halting cap-dependent mRNA translation.  
 PV mRNA, which does not possess a 5' cap, is translated via  
 cap-independent mechanisms within viral protease-modified messenger  
 ribonucleoprotein (mRNP) complexes. In this study, we determined that  
 2A(Pro) activity was required for viral polysome formation and stability.  
 2A(Pro) cleaved eIF4GI and eIF4GII as PV polysomes assembled. A  
 2A(Cys109Ser) (2A(Pro) with a Cys109Ser mutation)  
 protease active site mutation that prevented cleavage of  
 eIF4G coordinately inhibited the de novo formation of viral polysomes, the  
 stability of viral polysomes, and the stability of PV mRNA within  
 polysomes. 2A(Cys109Ser)-associated defects in PV mRNA and polysome  
 stability correlated with defects in PV mRNA translation. 3C(Pro) activity  
 was not required for viral polysome formation or stability.  
 2A(Pro)-mediated cleavage of eIF4G along with poly(rC) binding protein  
 binding to the 5' terminus of uncapped PV mRNA appear to be concerted  
 mechanisms that allow PV mRNA to form mRNP complexes that evade cellular  
 mRNA degradation machinery.

L11 ANSWER 3 OF 51 MEDLINE on STN DUPLICATE 3  
 AN 2008615010 MEDLINE  
 DN PubMed ID: 18710212  
 TI Automated molecular simulation based binding affinity calculator for  
 ligand-bound HIV-1 proteases.  
 AU Sadiq S Kashif; Wright David; Watson Simon J; Zasada Stefan J; Stoica  
 Ileana; Coveney Peter V  
 CS Centre for Computational Science, Department of Chemistry, University  
 College London, London, WC1H 0AJ, UK.  
 SO Journal of chemical information and modeling, (2008 Sep) Vol. 48, No. 9,  
 pp. 1909-19. Electronic Publication: 2008-08-19.  
 Journal code: 101230060. ISSN: 1549-9596.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 200811  
 ED Entered STN: 23 Sep 2008  
 Last Updated on STN: 18 Nov 2008  
 Entered Medline: 17 Nov 2008

AB The successful application of high throughput molecular simulations to determine biochemical properties would be of great importance to the biomedical community if such simulations could be turned around in a clinically relevant timescale. An important example is the determination of antiretroviral inhibitor efficacy against varying strains of HIV through calculation of drug-protein binding affinities. We describe the Binding Affinity Calculator (BAC), a tool for the automated calculation of HIV-1 protease-ligand binding affinities. The tool employs fully atomistic molecular simulations alongside the well established molecular mechanics Poisson-Boltzmann solvent accessible surface area (MMPBSA) free energy methodology to enable the calculation of the binding free energy of several ligand-protease complexes, including all nine FDA approved inhibitors of HIV-1 protease and seven of the natural substrates cleaved by the protease. This enables the efficacy of these inhibitors to be ranked across several mutant strains of the protease relative to the wildtype. BAC is a tool that utilizes the power provided by a computational grid to automate all of the stages required to compute free energies of binding: model preparation, equilibration, simulation, postprocessing, and data-marshaling around the generally widely distributed compute resources utilized. Such automation enables the molecular dynamics methodology to be used in a high throughput manner not achievable by manual methods. This paper describes the architecture and workflow management of BAC and the function of each of its components. Given adequate compute resources, BAC can yield quantitative information regarding drug resistance at the molecular level within 96 h. Such a timescale is of direct clinical relevance and can assist in decision support for the assessment of patient-specific optimal drug treatment and the subsequent response to therapy for any given genotype.

L11 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1535474 CAPLUS

DN 150:138397

TI The DEG15 serine protease cleaves peroxisomal targeting signal 2-containing proteins in Arabidopsis

AU Schuhmann, Holger; Huesgen, Pitter F.; Gietl, Christine; Adamska, Iwona  
CS Department of Physiology and Plant Biochemistry, University of Konstanz, Konstanz, DE-78457, Germany

SO Plant Physiology (2008), 148(4), 1847-1856  
CODEN: PLPHAY; ISSN: 0032-0889

PB American Society of Plant Biologists

DT Journal

LA English

AB Two distinct peroxisomal targeting signals (PTSs), the C-terminal PTS1 and the N-terminal PTS2, are defined. Processing of the PTS2 on protein import is conserved in higher eukaryotes. Recently, candidates for the responsible processing protease were identified from plants (DEG15) and mammals (TYSND1). We demonstrate that plants lacking DEG15 show an expressed phenotype potentially linked to reduced  $\beta$ -oxidation, indicating the impact of protein processing on peroxisomal functions in higher eukaryotes. Mutational anal. of Arabidopsis (*Arabidopsis thaliana*) DEG15 revealed that conserved histidine, aspartic acid, and serine residues are essential for the proteolytic activity of this enzyme in vitro. This indicates that DEG15 and related enzymes are trypsin-like serine endopeptidases. Deletion of a plant-specific stretch present in the protease domain diminished, but did not abolish, the proteolytic activity of DEG15 against the PTS2-containing glyoxysomal malate dehydrogenase. Fluorescence microscopy showed that a DEG15-green fluorescent protein fusion construct is targeted to peroxisomes in planta. In vivo studies with isolated homozygous *deg15* knockout mutants and complemented mutant lines suggest that this enzyme mediates general

processing of PTS2-containing proteins.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 51 MEDLINE on STN DUPLICATE 4  
AN 2008676424 MEDLINE  
DN PubMed ID: 18674574  
TI Sapovirus-like particles derived from polyprotein.  
AU Hansman Grant S; Oka Tomoichiro; Takeda Naokazu  
CS Department of Virology II, National Institute of Infectious Diseases,  
Japan.. g@nih.go.jp  
SO Virus research, (2008 Nov) Vol. 137, No. 2, pp. 261-5. Electronic  
Publication: 2008-08-15.  
Journal code: 8410979. ISSN: 0168-1702.  
CY Netherlands  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Priority Journals  
EM 200901  
ED Entered STN: 23 Oct 2008  
Last Updated on STN: 7 Jan 2009  
Entered Medline: 6 Jan 2009  
AB We expressed full-length sapovirus genome constructs in insect cells and  
analyzed their products. The capsid protein was cleaved from the ORF1  
polyprotein from a native-like genome construct and two full-length genome  
constructs with mutations in an active polymerase motif, whereas the  
capsid protein was not cleaved from a full-length genome construct with a  
mutation in an active protease motif. Our results  
showed that the sapovirus protease-polymerase precursor protein  
cleaved the capsid protein from the polyprotein at the putative  
conserved capsid start. Importantly, the cleaved capsid protein formed  
empty virus-like particles that were morphologically and antigenically  
similar to native sapovirus.

L11 ANSWER 6 OF 51 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights  
reserved on STN DUPLICATE 5  
AN 2009033996 EMBASE  
TI Design of mutation-resistant HIV protease inhibitors with the substrate  
envelope hypothesis.  
AU Chellappan, S.; Reddy, G.S.K.K.; Ali, A.  
SO Chemtracts, (March 2008) Vol. 21, No. 3, pp. 103-104.  
ISSN: 1431-9268 CODEN: CHEMFW  
PB Data Trace Publishing Company, 110 West Road, Ste. 227, Towson, Maryland,  
MD 21204-2316, United States.  
CY United States  
DT Journal; Article  
FS 004 Microbiology: Bacteriology, Mycology, Parasitology and Virology  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
ED Entered STN: 6 Feb 2009  
Last Updated on STN: 6 Feb 2009  
AB The introduction of human immunodeficiency virus protease (HIVP)  
inhibitors as therapeutic agents against HIV has considerably improved  
survival rate of acquired immunodeficiency syndrome (AIDS) patients.  
However, treatment using these inhibitors is hampered by the emergence of  
resistance mutations within the viral protease that decrease inhibitor  
affinity. Thus, to retain efficacy as anti-HIV drugs, the inhibitors must

retain the ability to bind to HIVP despite the presence of mutations in the enzyme. This article reports on the use of the so-called "substrate envelope hypothesis" as an approach to search for inhibitors of HIVP that remain effective despite the presence of resistance mutations. The natural substrates of the HIVP (i.e., sites in the Gag-Pol polyprotein that are cleaved by the protease) all occupy essentially the same area of the substrate binding site despite having differing amino acid sequences. Importantly, mutations that give rise to inhibitor resistance mostly lie outside this substrate envelope, presumably because mutations within the envelope would compromise the essential cleavage of the viral polyprotein. Thus, an inhibitor that fits within the envelope should be immune to resistance mutations. The investigators designed a combinatorial chemical library using computational methods and based on the hydroxyethylaminosulfonamide scaffold (Fig. 1) as a blueprint of the HIVP inhibitors. Additionally, the authors used combined docking and substrate envelope scores to identify and synthesize two compounds that were tested against wild-type and mutant HIV-1 protease for inhibitory activities (Fig. 2). The two compounds were determined to have considerable affinity against HIVP mutants, although lower than that of Amprenavir, which is better fitted to the conformation of the substrate envelope. .COPYRGHT. 2008 Data Trace Publishing Company.

L11 ANSWER 7 OF 51 MEDLINE on STN DUPLICATE 6  
 AN 2007239056 MEDLINE  
 DN PubMed ID: 17337448  
 TI Functional characterization of cis and trans activity of the Flavivirus NS2B-NS3 protease.  
 AU Bera Aloke K; Kuhn Richard J; Smith Janet L  
 CS Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907, USA.  
 NC P01 AI-055672 (United States NIAID NIH HHS)  
 SO The Journal of biological chemistry, (2007 Apr 27) Vol. 282, No. 17, pp. 12883-92. Electronic Publication: 2007-03-02.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 LA English  
 FS Priority Journals  
 EM 200706  
 ED Entered STN: 24 Apr 2007  
 Last Updated on STN: 15 Jun 2007  
 Entered Medline: 14 Jun 2007  
 AB Flaviviruses are serious human pathogens for which treatments are generally lacking. The proteolytic maturation of the 375-kDa viral polyprotein is one target for antiviral development. The flavivirus serine protease consists of the N-terminal domain of the multifunctional nonstructural protein 3 (NS3) and an essential 40-residue cofactor (NS2B(40)) within viral protein NS2B. The NS2B-NS3 protease is responsible for all cytoplasmic cleavage events in viral polyprotein maturation. This study describes the first biochemical characterization of flavivirus protease activity using full-length NS3. Recombinant proteases were created by fusion of West Nile virus (WNV) NS2B(40) to full-length WNV NS3. The protease catalyzed two autolytic cleavages. The NS2B/NS3 junction was cleaved before protein purification. A second site at Arg(459) decreasing Gly(460) within the C-terminal helicase region of NS3 was cleaved more slowly. Autolytic cleavage reactions also occurred in NS2B-NS3 recombinant proteins from yellow fever virus, dengue virus types 2 and 4, and Japanese encephalitis virus. Cis and trans cleavages were distinguished using a noncleavable WNV protease

variant and two types of substrates as follows: an inactive variant of recombinant WNV NS2B-NS3, and cyan and yellow fluorescent proteins fused by a dodecamer peptide encompassing a natural cleavage site. With these materials, the autolytic cleavages were found to be intramolecular only. Autolytic cleavage of the helicase site was insensitive to protein dilution, confirming that autolysis is intramolecular. Formation of an active protease was found to require neither cleavage of NS2B from NS3 nor a free NS3 N terminus. Evidence was also obtained for product inhibition of the protease by the cleaved C terminus of NS2B.

L11 ANSWER 8 OF 51 MEDLINE on STN DUPLICATE 7  
 AN 2007379218 MEDLINE  
 DN PubMed ID: 17475644  
 TI Identification of a Ca<sup>2+</sup>-binding domain in the rubella virus nonstructural protease.  
 AU Zhou Yubin; Tzeng Wen-Pin; Yang Wei; Zhou Yumei; Ye Yiming; Lee Hsiau-wei; Frey Teryl K; Yang Jenny  
 CS Department of Chemistry, Georgia State University, 50 Decatur St., Atlanta, GA 30303, USA.  
 NC GM070555 (United States NIGMS NIH HHS)  
 GM62999 (United States NIGMS NIH HHS)  
 R01 AI21389 (United States NIAID NIH HHS)  
 SO Journal of virology, (2007 Jul) Vol. 81, No. 14, pp. 7517-28. Electronic Publication: 2007-05-02.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC1933374.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, N.I.H., EXTRAMURAL)  
 (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 200709  
 ED Entered STN: 29 Jun 2007  
 Last Updated on STN: 15 Sep 2007  
 Entered Medline: 14 Sep 2007  
 AB The rubella virus (RUB) nonstructural protein (NS) open reading frame (ORF) encodes a polypeptide precursor that is proteolytically self cleaved into two replicase components involved in viral RNA replication. A putative EF-hand Ca(2+)-binding motif that was conserved across different genotypes of RUB was predicted within the nonstructural protease that cleaves the precursor by using bioinformatics tools. To probe the metal-binding properties of this motif, we used an established grafting approach and engineered the 12-residue Ca(2+)-coordinating loop into a non-Ca(2+)-binding scaffold protein, CD2. The grafted EF-loop bound to Ca(2+) and its trivalent analogs Tb(3+) and La(3+) with K(d)s of 214, 47, and 14 microM, respectively. Mutations (D1210A and D1217A) of two of the potential Ca(2+)-coordinating ligands in the EF-loop led to the elimination of Tb(3+) binding. Inductive coupled plasma mass spectrometry was used to confirm the presence of Ca(2+) ([Ca(2+) ]/[protein] = 0.7 +/- 0.2) in an NS protease minimal metal-binding domain, RUBCa, that spans the EF-hand motif. Conformational studies on RUBCa revealed that Ca(2+) binding induced local conformational changes and increased thermal stability (Delta T(m) = 4.1 degrees C). The infectivity of an RUB infectious cDNA clone containing the mutations D1210A/D1217A was decreased by approximately 20-fold in comparison to the wild-type (wt) clone, and these mutations rapidly reverted to the wt sequence. The NS protease containing these mutations was less efficient at precursor cleavage than the wt NS protease at 35 degrees C, and the mutant NS protease was temperature sensitive at 39 degrees C, confirming



that the Ca(2+)-binding loop played a structural role in the NS protease and was specifically required for optimal stability under physiological conditions.

L11 ANSWER 9 OF 51 MEDLINE on STN DUPLICATE 8  
AN 2006671183 MEDLINE  
DN PubMed ID: 17109345  
TI A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes.  
AU Soderholm Jonas; Sallberg Matti  
CS Division of Clinical Virology, Karolinska Institutet at Karolinska University Hospital Huddinge, S-141 86, Stockholm, Sweden.  
SO The Journal of infectious diseases, (2006 Dec 15) Vol. 194, No. 12, pp. 1724-8. Electronic Publication: 2006-11-03. Journal code: 0413675. ISSN: 0022-1899.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200701  
ED Entered STN: 21 Nov 2006  
Last Updated on STN: 18 Jan 2007  
Entered Medline: 17 Jan 2007  
AB The hepatitis C virus nonstructural (NS) 3/4A protease sequence is highly conserved for reasons not fully understood. We determined the protease activity in 181 NS3/4A gene products in which each protease residue was replaced by alanine or glycine. Unexpectedly, most (87%) protease residues could be replaced and protease activity would be retained. Using these data, we were able to identify a human leukocyte antigen A2-restricted epitope in which substitutions at 5 of 9 residues destroyed the protease. The NS3 protease shows an unexpectedly high plasticity, and it is therefore important to identify target sequences in which the appearance of mutations is restricted by viral fitness.

L11 ANSWER 10 OF 51 MEDLINE on STN DUPLICATE 9  
AN 2006574977 MEDLINE  
DN PubMed ID: 17003922  
TI In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.  
AU Donadelli Roberta; Banterla Federica; Galbusera Miriam; Capoferri Cristina; Bucchioni Sara; Gastoldi Sara; Nosari Silvia; Monteferrante Giuseppe; Ruggeri Zaverio M; Bresin Elena; Scheifflinger Friedrich; Rossi Edoardo; Martinez Constantino; Coppo Rosanna; Remuzzi Giuseppe; Noris Marina  
CS Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Villa Camozzi, Via Camozzi, 3, 24020 Ranica, Bergamo, Italy. (International Registry of Recurrent and Familial HUS/TTP).  
SO Thrombosis and haemostasis, (2006 Oct) Vol. 96, No. 4, pp. 454-64. Journal code: 7608063. ISSN: 0340-6245.  
CY Germany: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Priority Journals  
EM 200611  
ED Entered STN: 28 Sep 2006  
Last Updated on STN: 14 Nov 2006

Entered Medline: 13 Nov 2006

AB Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by microvascular thrombosis, often associated with deficiency of the vonWillebrand factor (VWF) cleaving protease ADAMTS13. We investigated the spectrum of ADAMTS13 gene mutations in patients with TTP and congenital ADAMTS13 deficiency to establish the consequences on ADAMTS13 processing and activity. We describe five missense (V88M, G1239V, R1060W, R1123C and R1219W), 1 nonsense (W1016Stop) and 1 insertion (82\_83insT) mutations. In two patients no mutation was identified despite undetectable protease activity. Expression in HEK293 mammalian cells (V88M, G1239V, R1123C and R1219W) documented that three missense mutants were not secreted, whereas the V88M was secreted at low levels and with reduced activity. We also provide evidence that impaired secretion of ADAMTS13 mutants observed in vitro translates into severely reduced ADAMTS13 antigen levels in patients in vivo. To evaluate whether the small amounts of mutant protease present in the circulation of patients had VWF cleaving activity, WT and mutant rADAMTS13 were stably expressed in Drosophila S2 cells under the influence of the Drosophila BiP protein signal sequence, which allows protein secretion. Drosophila expression system showed a 40-60% protease activity in the mutants. Several single nucleotide polymorphisms (SNPs) within exons and intron boundaries were found in patients, suggesting that the interplay of SNPs could at least in part account for ADAMTS13 functional abnormalities in patients without mutations. In conclusion, defective secretion and impaired activity of the mutants concur to determine an almost complete deficiency of ADAMTS13 activity in patients with a homozygous or two heterozygous ADAMTS13 mutations.

L11 ANSWER 11 OF 51 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

AN 2006:688128 SCISEARCH

GA The Genuine Article (R) Number: 060LK

TI Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals

AU Dev K K (Reprint)

CS Novartis Pharma AG, Novartis Inst BioMed Res, CH-4002 Basel, Switzerland (Reprint)

AU Chatterjee S; Osinde M; Stauffer D; Morgan H; Kobialko M; Dengler U; Rueeger H; Martoglio B; Rovelli G

CS E-mail: kumlesh\_k.dev@novartis.com

CYA Switzerland

SO EUROPEAN JOURNAL OF PHARMACOLOGY, (1 JUL 2006) Vol. 540, No. 1-3, pp. 10-17.

ISSN: 0014-2999.

PB ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.

DT Article; Journal

LA English

REC Reference Count: 28

ED Entered STN: 27 Jul 2006

Last Updated on STN: 19 Aug 2006

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB The intramembrane-cleaving proteases (I-CLiPs) presenilin-1 and -2 (PS1 and PS2), signal peptide peptidase (SPP) and the Site-2 protease (S2P) catalyze critical steps in cell signaling and are implicated in diseases such as Alzheimer's disease, hepatitis C virus (HCV) infection and cholesterol homeostasis. Here we describe the development of a cellular assay based on cleavage of the transmembrane sequence of the HCV core protein precursor, releasing intra- and extra-cellular signals that represent sequential signal peptidase and SPP cleavage, respectively. We find that the SPP inhibitor (Z-LL)2-ketone (IC50=1.33  $\mu$ M) and the gamma-secretase potent inhibitors NVP-AHW700-NX (IC50=51 nM) and LY411575

(IC50=61 nM) but not DAPT dose dependently inhibited SPP but not signal peptidase cleavage. Our data confirm that type 11 orientated substrates, like the HCV transmembrane sequence, are sequentially cleaved by signal peptidase then SPP. This dual assay provides a powerful tool to pharmacologically analyze sequential cleavage events of signal peptidase and SPP and their regulation. (c) 2006 Elsevier B.V All rights reserved.

L11 ANSWER 12 OF 51 MEDLINE on STN DUPLICATE 10  
 AN 2004621543 MEDLINE  
 DN PubMed ID: 15596836  
 TI Importance of arginine 20 of the swine vesicular disease virus 2A protease for activity and virulence.  
 AU Inoue Toru; Alexandersen Soren; Clark Angela T; Murphy Ciara; Quan Melvyn; Reid Scott M; Sakoda Yoshihiro; Johns Helen L; Belsham Graham J  
 CS Department of Exotic Disease, National Institute of Animal Health, Kodaira, Tokyo, Japan.  
 SO Journal of virology, (2005 Jan) Vol. 79, No. 1, pp. 428-40.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC538687.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LA English  
 FS Priority Journals  
 EM 200501  
 ED Entered STN: 20 Dec 2004  
 Last Updated on STN: 15 Jan 2005  
 Entered Medline: 14 Jan 2005  
 AB A major virulence determinant of swine vesicular disease virus (SVDV), an Enterovirus that causes an acute vesicular disease, has been mapped to residue 20 of the 2A protease. The SVDV 2A protease cleaves the 1D-2A junction in the viral polyprotein, induces cleavage of translation initiation factor eIF4GI, and stimulates the activity of enterovirus internal ribosome entry sites (IRESs). The 2A protease from an attenuated strain of SVDV (Ile at residue 20) is significantly defective at inducing cleavage of eIF4GI and the activation of IRES-dependent translation compared to the 2A protease from a pathogenic strain (J1/73, Arg at residue 20), but the two proteases have similar 1D-2A cleavage activities (Y. Sakoda, N. Ross-Smith, T. Inoue, and G. J. Belsham, J. Virol. 75:10643-10650, 2001). Residue 20 has now been modified to every possible amino acid, and the activities of each mutant 2A protease has been analyzed. Selected mutants were reconstructed into full-length SVDV cDNA, and viruses were rescued. The rate of virus growth in cultured swine kidney cells reflected the efficiency of 2A protease activity. In experimentally infected pigs, all four of the mutant viruses tested displayed much-reduced virulence compared to the J1/73 virus but a significant, albeit reduced, level of viral replication and excretion was detected. Direct sequencing of cDNA derived from samples taken early and late in infection indicated that a gradual selection-reversion to a more efficient protease occurred. The data indicated that extensive sequence change and selection may introduce a severe bottleneck in virus replication, leading to a decreased viral load and reduced or no clinical disease.

L11 ANSWER 13 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN  
 AN 2006:136357 BIOSIS  
 DN PREV200600132370  
 TI The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 leads to a secretion defect.  
 AU Peyvandi, Flora [Reprint Author]; Lavoretano, Silvia; Palla, Roberta;

Garagiola, Isabella; Valsecchi, Carla; Lombardi, Rossana; Canciani, Maria T.; Mannucci, Pier M.

CS Univ Milan, Maggiore Hosp, IRCCS Fdn, Fdn L Villa, A Bianchi Bonomi Hemophilia and Thrombo, Milan, Italy

SO Blood, (NOV 16 2005) Vol. 106, No. 11, Part 2, pp. 69B-70B.  
Meeting Info.: 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol.  
CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 22 Feb 2006

Last Updated on STN: 22 Feb 2006

AB The inherited deficiency of the von Willebrand factor-cleaving protease, ADAMTS 13, is usually associated with severe forms of thrombotic thrombocytopenic purpura (TTP). Among the reported 53 mutations on ADAMTS13 gene, none has been described on TSP1-6 repeat domain. We investigated an Iranian man with history of chronic recurrent TTP and very low plasma levels of ADAMTS 13 activity (2.3%). He had his first TTP episode at the age of 21 years and 6 subsequent episodes occurred without precipitating events. Genetic analysis revealed a homozygous deletion of nucleotides 2930-2935 (GTGCCC), in exon 23 of ADAMTS13 gene, leading to the replacement of Cys977 residue by a Trp and the deletion of Ala978 and Arg979, in the TSP1-6 repeat domain. The patient's brother, homozygous for the same mutation, has no clinical manifestation of TTP so far, despite the same degree of ADAMTS 13 deficiency. The patient's parents resulted to be heterozygous. To explore the mechanism of ADAMTS13 deficiency, wild type (ADAMT13(WT)) and mutant (ADAMTS 13(del6bp)) expression vectors were transiently transfected in HEK293 and COS-7 cells. The enzymatic activity of the expressed rADAMTS13 proteins was evaluated by measuring the extent of VWF multimer degradation, using a quantitative immunoblotting assay. rADAMT13(WT) was able to degrade multimers completely (100% of activity), whereas rADAMTS13(del6bp) had enzymatic activity reduced to similar to 10% of WT. Both WT and mutant proteases present in conditioned media and cell lysates, were analyzed by Western blot analysis, using anti-V5 monoclonal antibody against the C-terminal tag of rADAMTS13. Blots showed a dense band of similar to 190 KDa in the medium, corresponding to the secreted rADAMT13(WT) protein. Cells transfected with ADAMTS(13del6bp) showed a fainter band roughly estimated to be 5% of the WT obtained by densitometric analysis. Therefore, pulse-chase labelling experiments were performed to evaluate the presence of a secretion pathway alteration. After 60 min pulse with [<sup>35</sup>S] methionine the maximum level of rADAMT13(WT) in conditioned media was found at 24 hours. rADAMTS13(del6bb), was minimally present after 3 hours only, no band being detected after 7 hours of chase. Differential immunofluorescence studies were performed using an anti-V5 monoclonal antibody against ADAMTS13 proteins and monoclonal antibodies recognizing markers of Cis-Golgi and ER. The merging studies in WT and mutant transfected cells showed that rADAMTS 13, was mostly localized in the perinuclear area, suggesting a primary localization in the Golgi apparatus, whereas rADAMTS13(del6bp), showed less intense staining diffusely throughout the cytoplasm, only a minimal amount of the mutant protein being localized in the Cis-Golgi and ER. The structural consequences of the deletion mutation in the TSP1-6 domain may cause a loss of the known antiparallel, three-stranded fold characterizing the architecture of the TSP-like domains. In these domains, each strand is capped by disulfide bonds on each end. This study suggests that the residue Cys977 could be involved in the formation of disulphide bonds responsible for a correct folding of one of the TSP1-like domains of ADAMTS13. Therefore the deletion could lead to uncorrected folding which reflects an intracellular degradation and secretion defect of the

mutant protease without any intracellular accumulation.  
These results reflect the severe deficiency of ADAMTS 13 in the patient's plasma.

L11 ANSWER 14 OF 51 MEDLINE on STN DUPLICATE 11  
AN 2004044470 MEDLINE  
DN PubMed ID: 14744894  
TI Pseudomonas keratitis: protease IV gene conservation, distribution, and production relative to virulence and other Pseudomonas proteases.  
AU Caballero Armando; Thibodeaux Brett; Marquart Mary; Traidej Mullika; O'Callaghan Richard  
CS Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.  
NC EY12961 (United States NEI NIH HHS)  
SO Investigative ophthalmology & visual science, (2004 Feb) Vol. 45, No. 2, pp. 522-30.  
Journal code: 7703701. ISSN: 0146-0404.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LA English  
FS Priority Journals  
EM 200402  
ED Entered STN: 28 Jan 2004  
Last Updated on STN: 13 Feb 2004  
Entered Medline: 12 Feb 2004  
AB PURPOSE: To determine the distribution of the protease IV gene, the production of this and other proteases by multiple strains of Pseudomonas, and the virulence of a mutant specifically deficient in protease IV. METHODS: The protease IV gene was cloned, its sequence analyzed, and its chromosomal location determined by pulse-field gel electrophoresis. Three PCR reactions were used to detect the protease IV gene in 30 Pseudomonas isolates and protease production was determined by Western blot analysis, colorimetric assay, and zymography. An allelic replacement mutant deficient in the protease IV gene was analyzed for enzyme production, corneal growth, and corneal virulence. RESULTS: The protease IV gene was identified in all P. aeruginosa, but none of the non-aeruginosa strains tested. The protease IV genes of strains PA103-29 and PAO1 were in a common chromosomal site and had 98.5% sequence identity with variations occurring mainly in the promoter region. The protease IV activity of the 23 wild-type P. aeruginosa strains tested varied from 2.3 to 221.5 x 10<sup>-3</sup> U/mg protein in the culture supernatant. Protease IV was produced by all P. aeruginosa wild-type strains. A protease IV-deficient mutant derived from strain PA103-29 had reduced virulence compared with its parent strain and unexpectedly produced alkaline protease. CONCLUSIONS: The protease IV gene and its product are common to P. aeruginosa, but not to other Pseudomonas species. Protease IV activity varies among P. aeruginosa strains, and a mutant specifically deficient in this activity produced alkaline protease and had reduced corneal virulence.

L11 ANSWER 15 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN  
AN 2005:476582 BIOSIS  
DN PREV200510268486  
TI Diverse functional implications of ADAMTS13 gene mutations in patients with TTP and congenital deficiency.  
AU Donadelli, Roberta [Reprint Author]; Banterla, Federica; Capoferri, Cristina; Galbusera, Miriam; Ruggeri, Zaverici M.; Bucchioni, Sara; Noris, Marina; Remuzzi, Giuseppe  
CS Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy

SO Blood, (NOV 16 2004) Vol. 104, No. 11, Part 1, pp. 149A.  
Meeting Info.: 46th Annual Meeting of the American-Society-of-Hematology.  
San Diego, CA, USA. December 04 -07, 2004. Amer Soc Hematol.  
CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 16 Nov 2005  
Last Updated on STN: 16 Nov 2005

AB Thrombotic thrombocytopenic purpura (TTP) is a rare disorder of small  
vessels that is associated with deficiency of the VWF cleaving  
protease ADAMTS 13, causing life-threatening disseminated  
microvascular thrombosis. Here we report four missense mutations (V88M,  
G1239V, R1219W, R1123C) in three patients with congenital ADAMTS 13  
deficiency. The three subjects carrying the mutations had less than 10%  
normal ADAMTS 13 plasma antigen levels (measured by ELISA), which is  
consistent with previously reported data showing that most ADAMTS 13  
mutations in TTP patients result in impaired secretion of the protein. To  
evaluate whether the small amount of the mutant protease  
present in patients' plasma had proteolytic activity, we cloned the ADAMTS  
13 cDNA in the pMT/ Bip/His Drosophila expression vector and introduced  
the respective mutations by directed mutagenesis technique using wild-type  
cDNA as a template. These wild-type and mutant constructs were stably  
transfected into S2 Drosophila cells under the influence of the Drosophila  
BiP protein signal sequence, which allows the protein to be secreted into  
the medium and overcomes impaired secretion caused by the mutations. The  
induction of the histidine-tagged ADAMTS 13 recombinants following the  
addition of copper was analyzed by Western blotting using an  
anti-hexahistidine monoclonal antibody. Equal amounts of recombinant  
ADAMTS 13 proteins were used to evaluate proteolytic activity of  
recombinant proteins by cleavage of the rVWF A1-A2-A3 substrate. The  
proteolytic carboxyl terminal product of about 30 kDa was visualized by  
Western blot with a mouse monoclonal antibody directed against an epitope  
contained within the A3 domain of VWF. All the four missense mutations  
exhibited reduced activity: V88M:40%, G1239V: 66%, R1219W: 62% and R1123C:  
64% of wild type activity. The results were also confirmed by collagen  
binding assay. For the V88M mutation (located in the metalloprotease  
domain), decreased activity was confirmed by kinetic studies. In  
conclusion, mutant ADAMTS13 proteins found in patients with TTP besides  
defective secretion, also have reduced protease activity. The mechanisms  
of the deficiency will be the matter of further studies.

L11 ANSWER 16 OF 51 MEDLINE on STN DUPLICATE 12

AN 2003477593 MEDLINE

DN PubMed ID: 12874290

TI The Staphostatin-staphopain complex: a forward binding inhibitor in  
complex with its target cysteine protease.

AU Filipek Renata; Rzychon Malgorzata; Oleksy Aneta; Gruca Milosz; Dubin  
Adam; Potempa Jan; Bochtler Matthias

CS International Institute of Molecular and Cell Biology, ul Trojdena 4,  
02-109 Warsaw, Poland.

SO The Journal of biological chemistry, (2003 Oct 17) Vol. 278, No. 42, pp.  
40959-66. Electronic Publication: 2003-07-21.  
Journal code: 2985121R. ISSN: 0021-9258.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

OS PDB-1PXV

EM 200312

ED Entered STN: 15 Oct 2003  
 Last Updated on STN: 19 Dec 2003  
 Entered Medline: 3 Dec 2003

AB Staphostatins are the endogenous inhibitors of the major secreted cysteine proteases of *Staphylococcus aureus*, the staphopains. Our recent crystal structure of staphostatin B has shown that this inhibitor forms a mixed, eight-stranded beta-barrel with statistically significant similarity to lipocalins, but not to cystatins. We now present the 1.8-A crystal structure of staphostatin B in complex with an inactive mutant of its target protease. The complex is held together through extensive interactions and buries a total surface area of 2300 A<sup>2</sup>. Unexpectedly for a cysteine protease inhibitor, staphostatin B binds to staphopain B in an almost substrate-like manner. The inhibitor polypeptide chain runs through the protease active site cleft in the forward direction, with residues IG-TS in P2 to P2' positions. Both in the free and complexed forms, the P1 glycine residue of the inhibitor is in a main chain conformation only accessible to glycines. Mutations in this residue lead to a loss of affinity of the inhibitor for protease and convert the inhibitor into a substrate.

L11 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:416281 CAPLUS  
 DN 139:115648  
 TI ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity  
 AU Savasan, Sureyya; Lee, Soon-Ki; Ginsburg, David; Tsai, Han-Mou  
 CS Children's Hospital of Michigan, Division of Hematology/Oncology, Wayne State University, Detroit, MI, USA  
 SO Blood (2003), 101(11), 4449-4451  
 CODEN: BLOOAW; ISSN: 0006-4971  
 PB American Society of Hematology  
 DT Journal  
 LA English  
 AB Deficiency of von Willebrand factor (VWF) cleaving protease ADAMTS13 is associated with the development of thrombotic thrombocytopenic purpura (TTP). A case of congenital TTP that was previously reported to have normal ADAMTS13 activity was analyzed at the mol. level. Reanal. of plasma VWF cleaving protease activity using a different assay revealed that the patient had less than 0.1 U/L ADAMTS13 protease activity, while the parents were both partially deficient. Sequence anal. of DNA amplified by polymerase chain reaction showed that the patient was homozygous for a novel TT deletion in exon 15 of the ADAMTS13 gene resulting in a frameshift, while both parents were heterozygous for the same mutation. Taken together with other recent reports, all the cases of hereditary TTP studied by DNA sequence anal. to date appear to be due to mutations within the ADAMTS13 gene.

OSC.G 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)  
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:174850 CAPLUS  
 DN 138:335598  
 TI Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP  
 AU Schneppenheim, Reinhard; Budde, Ulrich; Oyen, Florian; Angerhaus, Dorothea; Aumann, Volker; Drewke, Elke; Hassenpflug, Wolf; Haberle, Johannes; Kentouche, Karim; Kohne, Elisabeth; Kurnik, Karin; Mueller-Wiefel, Dirk; Obser, Tobias; Santer, Rene; Sykora, Karl-Walter  
 CS Children's University Hospital, Hamburg-Eppendorf, Germany  
 SO Blood (2003), 101(5), 1845-1850

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

AB Thrombotic thrombocytopenic purpura (TTP) is caused by the persistence of the highly reactive high-mol.-weight multimers of von Willebrand factor (VWF) due to deficiency of the specific VWF-cleaving protease (VWF-CP) ADAMTS13, resulting in microangiopathic disease. The acquired form is caused by autoantibodies against VWF-CP, whereas homozygous or compound heterozygous mutations of ADAMTS13 are responsible for recessively inherited TTP. We investigated 83 children with hemolytic or thrombocytopenic episodes with or without addnl. neurol. symptoms or renal failure. The presumed diagnosis was chronic idiopathic thrombocytopenic purpura (ITP; n = 50), TTP (n = 8), hemolytic uremic syndrome (HUS; n = 24), and Evans syndrome (n = 1). A severe deficiency of VWF-CP ( $\leq 5\%$ ) was found in all investigated patients with TTP and in none of those with HUS. Addnl., 2 of 50 patients with a prior diagnosis of ITP were deficient for VWF-CP. Antibodies against VWF-CP were found in 4 children. Mutation anal. of the ADAMTS13 gene in the patients deficient in VWF-CP by direct sequencing of all 29 exons identified 8 different mutations, suggesting the hereditary form of TTP in 1 patient with ITP, in the patient with Evans syndrome, and in 5 of the 8 patients with TTP. The phenotype of TTP in childhood can be rather variable. Besides the classical clin. picture, oligosymptomatic forms may occur that can delay the identification of patients at risk.

OSC.G 73 THERE ARE 73 CAPLUS RECORDS THAT CITE THIS RECORD (73 CITINGS)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 51 MEDLINE on STN DUPLICATE 13

AN 2003327749 MEDLINE

DN PubMed ID: 12858075

TI An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.

AU Yarranton Helen; Machin Samuel J

CS Haemostasis Research Unit, Department of Haematology, University College London, London, UK.

SO Current opinion in neurology, (2003 Jun) Vol. 16, No. 3, pp. 367-73. Ref: 48

Journal code: 9319162. ISSN: 1350-7540.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200308

ED Entered STN: 15 Jul 2003

Last Updated on STN: 16 Aug 2003

Entered Medline: 15 Aug 2003

AB PURPOSE OF REVIEW: Thrombotic thrombocytopenic purpura, a clinical syndrome characterized by thrombocytopenia and microangiopathic haemolytic anaemia, was almost universally fatal until the introduction of plasma exchange therapy in the 1970s. Current outcomes have improved dramatically with the initiation of prompt plasma exchange, a treatment routinely used without any real understanding of why it is effective. RECENT FINDINGS: Recent advances suggest that a deficiency of a specific plasma metalloprotease, responsible for the physiological processing of von Willebrand factor multimers, plays a substantial role in the pathogenesis of congenital and acquired idiopathic thrombotic thrombocytopenic purpura. The von Willebrand factor-cleaving protease has now been identified as a new member of the ADAMTS family of metalloproteases, designated ADAMTS13. The acquired form of



thrombotic thrombocytopenic purpura is associated with inhibitory autoantibodies against ADAMTS13, and the congenital chronic relapsing form is caused by mutations in the ADAMTS13 gene, resulting in a constitutional deficiency. Plasma exchange has been proved to be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data for adjunctive therapies, such as corticosteroids, antiplatelet drugs and other immunosuppressive agents often used in combination with plasma exchange, are less well defined. SUMMARY: Recent advances in our understanding of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale for the previously empirical plasma exchange therapy (removal of the inhibitory antibodies and replacement of the deficient protease from the plasma infused), but may also help in developing more rational and targeted treatment strategies. This review discusses the clinical presentation, pathophysiology and current management of thrombotic thrombocytopenic purpura.

- L11 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:294313 CAPLUS  
 DN 139:50682  
 TI TTP and ADAMTS13 mutation  
 AU Fujimura, Yoshihiro  
 CS Affiliated Hospital, Nara Prefectural Medical University, Japan  
 SO Annual Review Ketsueki (2003) 153-162  
 CODEN: ARKNB7  
 PB Chugai Igakusha  
 DT Journal; General Review  
 LA Japanese  
 AB A review on von Willebrand factor (vWF) cleaving protease ADAMTS13 mutation in thrombotic thrombocytopenic purpura (TTP). The topics discussed are (1) unusually large vWF multimers in TTP; (2) vWF cleaving protease activity and its IgG type inhibitor; (3) TTP vs. Upshaw-Schulman syndrome; and (4) von Willebrand factor cleaving protease ADAMTS13 and its mutation in TTP.
- L11 ANSWER 21 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN  
 AN 2002:558135 BIOSIS  
 DN PREV200200558135  
 TI Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  
 AU Kokame, Koichi; Matsumoto, Masanori; Soejima, Kenji; Yagi, Hideo; Ishizashi, Hiromichi; Funato, Masahisa; Tamai, Hiroshi; Konno, Mutsuko; Kamide, Kei; Kawano, Yuhei; Miyata, Toshiyuki [Reprint author]; Fujimura, Yoshihiro  
 CS Research Institute, National Cardiovascular Center, Suita, Osaka, 565-8565, Japan  
 miyata@ri.ncvc.go.jp  
 SO Proceedings of the National Academy of Sciences of the United States of America, (September 3, 2002) Vol. 99, No. 18, pp. 11902-11907. print.  
 CODEN: PNASA6. ISSN: 0027-8424.  
 DT Article  
 LA English  
 ED Entered STN: 30 Oct 2002  
 Last Updated on STN: 30 Oct 2002  
 AB von Willebrand factor (VWF) is synthesized primarily in vascular endothelial cells and secreted into the plasma as unusually large VWF multimers. Normally, these multimers are quickly degraded into smaller forms by a plasma metalloproteinase, VWF-cleaving protease (VWF-CP). Decreases in the activity of this enzyme result in congenital and acquired

thrombotic thrombocytopenic purpura (TTP). The human VWF-CP has recently been purified. Cloning of the corresponding cDNA revealed that the 1,427-aa polypeptide is a member of the ADAMTS gene family, termed ADAMTS13. Twelve rare mutations in this gene have been identified in patients with congenital TTP. Here, we report missense and nonsense mutations in two Japanese families with Upshaw-Schulman syndrome, congenital TTP with neonatal onset and frequent relapses. The comparison of individual ADAMTS13 genotypes and plasma VWF-CP activities indicated that the R268P, Q449stop, and C508Y mutations abrogated activity of the enzyme, whereas the P475S mutant retained low but significant activity. The effects of these mutations were further confirmed by expression analysis in HeLa cells. Recombinant VWF-CP containing either the R268P or C508Y mutations was not secreted from cells. In contrast, Q449stop and P475S mutants were normally secreted but demonstrated minimal activity. Genotype analysis of 364 Japanese subjects revealed that P475S is heterozygous in 9.6% of individuals, suggesting that approximately 10% of the Japanese population possesses reduced VWF-CP activity. We report on a single-nucleotide polymorphism associated with alterations in VWF-CP activity; it will be important to assess this single-nucleotide polymorphism as a risk factor for thrombotic disorders.

L11 ANSWER 22 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on  
STN  
AN 2002:369748 BIOSIS  
DN PREV200200369748  
TI Novel mechanism of activity control of potyvirus NIa protease.  
AU Han, Jisun [Reprint author]; Kang, Hyun-Jin [Reprint author]; Song,  
Byeong-Doo; Choi, Kwan-Yong [Reprint author]  
CS Life Science, Pohang University of Science and Technology, Hyo-ja Dong San  
31, Pohang, Kyungbuk, 790-784, South Korea  
SO FASEB Journal, (March 22, 2002) Vol. 16, No. 5, pp. A905. print.  
Meeting Info.: Annual Meeting of Professional Research Scientists on  
Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.  
CODEN: FAJOEC. ISSN: 0892-6638.  
DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LA English  
ED Entered STN: 3 Jul 2002  
Last Updated on STN: 3 Jul 2002  
AB Potato virus a (PVA) is a member of the potyvirus that belongs to the  
picornavirus superfamily of positive-stranded RNA viruses. The viral  
genome has one open reading frame that is translated into a polyprotein.  
The nuclear inclusion protein a (NIa) protease plays a key role in the  
potyviral life cycle by processing the viral polyprotein into functional  
proteins in cis or in trans. Among seven cleavage sites of NIa protease,  
the peptides representing VPg/NIaPro junction (V peptide) and NIa/NIB  
junction (E peptide) were processed only in cis. Investigation of the  
kinetics of NIa protease-peptide interactions revealed that the V peptide  
and E peptide acted like a competitive inhibitor for the reaction in which  
the peptide representing NIB/CP junction was used as a substrate. These  
results indicate that the peptides containing the cis-cleavage site  
sequences can strongly bind to the active site of the protease  
but are not cleaved by the enzyme. Kinetic analyses of  
mutant NIa protease combined with in vitro translation  
experiments suggest that the active site of the NIa protease is no longer  
occupied with the C-terminal four amino acids (P1-P4) after the  
cis-cleavage reaction between the NIa and NIB.

L11 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2002:526312 CAPLUS  
DN 138:219418

TI Predicting response to plasma exchange in patients with thrombotic  
 thrombocytopenic purpura with measurement of vWF-cleaving protease  
 activity  
 AU Mori, Yoshitaka; Wada, Hideo; Gabazza, Esteban C.; Minami, Nobuyuki;  
 Nobori, Tsutomu; Shiku, Hiroshi; Yagi, Hideo; Ishizashi, Hiromichi;  
 Matsumoto, Masanori; Fujimura, Yoshihiro  
 CS Mie Red Cross Blood Center, Department of Clinical Laboratory and Second  
 Department of Internal Medicine, Mie University School of Medicine, Tsu  
 City, 514-8507, Japan  
 SO Transfusion (Malden, MA, United States) (2002), 42(5), 572-580  
 CODEN: TRANAT; ISSN: 0041-1132  
 PB Blackwell Publishing, Inc.  
 DT Journal  
 LA English  
 AB Severe deficiency of vWF-cleaving protease (vWF-CPase) activity was  
 recently found in patients with thrombotic thrombocytopenic purpura (TTP).  
 Although the survival of patients with TTP has been dramatically improved  
 with plasma exchange (PE), there are still many patients who are  
 refractory to PE and immunosuppressive therapy. The activities of  
 vWF-CPase and its inhibitor were measured in 27 patients with nonfamilial  
 TTP and hemolytic-uremic syndrome (HUS) to examine the relationship  
 between the clin. variables and vWF-CPase activity. Eight of nine  
 patients with HUS had more than 40 % of vWF-CPase activity, whereas one  
 had 28 % of the normal level at the acute phase. Ten of 12 TTP patients  
 with a good outcome had a severe deficiency of vWF-CPase activity and its  
 inhibitor, whereas four of six patients with a poor outcome had a moderate  
 deficiency of vWF-CPase activity along with a lack of the inhibitor. PE  
 produced normalization of the vWF-CPase activity and neutralization of the  
 inhibitor in TTP patients with a good outcome; however, some TTP patients  
 with vWF-CPase inhibitor had relapsed and required an immunosuppressive  
 therapy. The response to the combination therapy with PE and  
 immunosuppressive treatment was poor in TTP patients without a severe  
 deficiency of vWF-CPase activity. Assays of vWF-CPase activity and its  
 inhibitor may be useful for predicting the response to therapy and the  
 outcome of patients with TTP. In some patients, nonfamilial TTP with a  
 poor prognosis may not be caused by a constitutional or acquired  
 deficiency of vWF-CPase with its inhibitor. Although PE and  
 immunosuppressive therapy are effective in patients with nonfamilial TTP  
 and a vWF-CPase inhibitor, other therapeutic modalities may be needed for  
 nonfamilial TTP with unknown etiol.  
 OSC.G 37 THERE ARE 37 CAPLUS RECORDS THAT CITE THIS RECORD (37 CITINGS)  
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 51 MEDLINE on STN DUPLICATE 14  
 AN 2003023698 MEDLINE  
 DN PubMed ID: 12530635  
 TI Identification of two alternate splice variants of a novel serine protease  
 expressed in steroidogenic tissues.  
 AU Omer Selma; Lomthaisong Khomsorn; Bicknell Andrew B  
 CS School of Animal and Microbial Sciences, The University of Reading,  
 Whiteknights, P.O. Box 228, Reading RG6 6AJ, UK.  
 SO Endocrine research, (2002 Nov) Vol. 28, No. 4, pp. 339-48.  
 Journal code: 8408548. ISSN: 0743-5800.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200307  
 ED Entered STN: 18 Jan 2003  
 Last Updated on STN: 17 Jul 2003

Entered Medline: 16 Jul 2003

AB During the search for the serine protease that cleaves pro-gamma-melatonin to stimulate adrenal growth, we identified another novel protease, which we called Adrenal mitochondrial protease (AmP). In situ hybridisation detected AmP transcripts in steroidogenic tissues such as the brain, testis, in ovarian follicles as well as in the adrenal cortex. Full length cloning identified two splice variants differing by a 222 nucleotide insertion in the 5' end of the short variant. The shorter variant codes for a 371 amino acid protein of 40.7 kDa and computer analysis predicts it to be targeted to the cytosol while the longer 445 amino acid protein of 48.4 kDa is mitochondrial. Cellular targeting was confirmed by tagging with GFP. The short variant was clearly cytosolic however, the cells expressing AmP-Long had large vacuoles, possibly as a result of distended (apoptotic?) mitochondria. Due to the mitochondrial localisation of the long variant of the protease and its expression in steroidogenic tissues, it may be expected to be involved in the steroidogenic pathway, possibly by cleaving steroidogenic acute regulatory protein (StAR). We investigated this by co-transfecting AmP-Long with StAR and F2 plasmid into COS-1 cells and measuring the effect on pregnenolone production. It was found that AmP-Long has no effect on steroidogenesis nor cleaves StAR as was shown by western blot analysis using StAR antibody.

L11 ANSWER 25 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

AN 2002:545058 BIOSIS

DN PREV200200545058

TI Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.

AU Lunkes, Astrid [Reprint author]; Lindenberg, Katrin S.; Ben-Haiem, Lea; Weber, Chantal; Devys, Didier; Landwehrmeyer, G. Bernhard; Mandel, Jean-Louis; Trottier, Yvon

CS European Molecular Biology Organization, Meyerhofstrasse 1, 69117, Heidelberg, Germany

astrid.lunkes@embo.org; yvon@igbmc.u-strasbg.fr

SO Molecular Cell, (August, 2002) Vol. 10, No. 2, pp. 259-269. print. ISSN: 1097-2765.

DT Article

LA English

ED Entered STN: 23 Oct 2002

Last Updated on STN: 23 Oct 2002

AB Proteolytic processing of mutant huntingtin (mhtt) is regarded as a key event in the pathogenesis of Huntington's disease (HD). Mhtt fragments containing a polyglutamine expansion form intracellular inclusions and are more cytotoxic than full-length mhtt. Here, we report that two distinct mhtt fragments, termed cp-A and cp-B, differentially build up nuclear and cytoplasmic inclusions in HD and in a cellular model for HD. Cp-A is released by cleavage of htt in a 10 amino acid domain and is the major fragment that aggregates in the nucleus. Furthermore, we provide evidence that cp-A and cp-B are most likely generated by aspartic endopeptidases acting in concert with the proteasome to ensure the normal turnover of htt. These proteolytic processes are thus potential targets for therapeutic intervention in HD.

L11 ANSWER 26 OF 51 MEDLINE on STN DUPLICATE 15

AN 2002334152 MEDLINE

DN PubMed ID: 12077234

TI Exogenous peptides delivered by ricin require processing by signal peptidase for transporter associated with antigen processing-independent MHC class I-restricted presentation.

AU Smith Daniel C; Gallimore Awen; Jones Emma; Roberts Brenda; Lord J

Michael; Deeks Emma; Cerundolo Vincenzo; Roberts Lynne M  
CS Department of Biological Sciences, University of Warwick, Coventry, United Kingdom.  
SO Journal of immunology (Baltimore, Md. : 1950), (2002 Jul 1) Vol. 169, No. 1, pp. 99-107.  
Journal code: 2985117R. ISSN: 0022-1767.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 200208  
ED Entered STN: 23 Jun 2002  
Last Updated on STN: 14 Aug 2002  
Entered Medline: 13 Aug 2002  
AB In this study we demonstrate that a disarmed version of the cytotoxin ricin can deliver exogenous CD8(+) T cell epitopes into the MHC class I-restricted pathway by a TAP-independent, signal peptidase-dependent pathway. Defined viral peptide epitopes genetically fused to the N terminus of an attenuated ricin A subunit (RTA) that was reassociated with its partner B subunit were able to reach the early secretory pathway of sensitive cells, including TAP-deficient cells. Successful processing and presentation by MHC class I proteins was not dependent on proteasome activity or on recycling of MHC class I proteins, but rather on a functional secretory pathway. Our results demonstrated a role for signal peptidase in the generation of peptide epitopes associated at the amino terminus of RTA. We showed, first, that potential signal peptide cleavage sites located toward the N terminus of RTA can be posttranslationally cleaved by signal peptidase and, second, that mutation of one of these sites led to a loss of peptide presentation. These results identify a novel MHC class I presentation pathway that exploits the ability of toxins to reach the lumen of the endoplasmic reticulum by retrograde transport, and suggest a role for endoplasmic reticulum signal peptidase in the processing and presentation of MHC class I peptides. Because TAP-negative cells can be sensitized for CTL killing following retrograde transport of toxin-linked peptides, application of these results has direct implications for the development of novel vaccination strategies.

L11 ANSWER 27 OF 51 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN  
AN 2003:572784 SCISEARCH  
GA The Genuine Article (R) Number: 614JK  
TI Determination of von Willebrand factor cleaving protease and ADAMTS13 mutation screening in the differential diagnosis of hemolytic-thrombocytopenic disorders in childhood.  
AU Schneppenheim R (Reprint); Budde U; Oyen F; Angerhaus D; Aumann V; Drewke E; Hassenpflug W A; Haberle J; Kentouche K; Kohne E; Kurnik K; Mueller-Wiefel D E; Obser T; Santer R; Sykora K W  
CS Childrens Univ Hosp, Hamburg, Germany; Lab Assoc Prof Arndt & Partners, Coagulat Lab, Hamburg, Germany; Childrens Univ Hosp, Magdeburg, Germany; Childrens Univ Hosp, Munster, Germany; Childrens Univ Hosp, Jena, Germany; Childrens Univ Hosp, Ulm, Germany; Childrens Univ Hosp, Munich, Germany; Childrens Univ Hosp, Kiel, Germany; Hannover Med Sch, D-3000 Hannover, Germany  
CYA Germany  
SO BLOOD, (16 NOV 2002) Vol. 100, No. 11, Part 1, pp. 56A-56A. MA 201. ISSN: 0006-4971.  
PB AMER SOC HEMATOLOGY, 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA.  
DT Conference; Journal

LA English  
REC Reference Count: 0  
ED Entered STN: 25 Jul 2003  
Last Updated on STN: 25 Jul 2003

L11 ANSWER 28 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

AN 2003:337362 BIOSIS

DN PREV200300337362

TI Determination of Von Willebrand Factor Cleaving Protease and ADAMTS13 Mutation Screening in the Differential Diagnosis of Hemolytic-Thrombocytopenic Disorders in Childhood.

AU Schneppenheim, Reinhard [Reprint Author]; Budde, Ulrich [Reprint Author]; Oyen, Florian [Reprint Author]; Angerhaus, Dorte [Reprint Author]; Aumann, Volker [Reprint Author]; Drewke, Elke [Reprint Author]; Hassenpflug, Wolf A. [Reprint Author]; Haberle, Johannes [Reprint Author]; Kentouche, Karim [Reprint Author]; Kohne, Elisabeth [Reprint Author]; Kurnik, Karin [Reprint Author]; Mueller-Wiefel, Dirk E. [Reprint Author]; Obser, Tobias [Reprint Author]; Santer, Rene [Reprint Author]; Sykora, Karl-Walter [Reprint Author]

CS Pediatric Hematology and Oncology, Children's University Hospital Hamburg, Hamburg, Germany

SO Blood, (November 16 2002) Vol. 100, No. 11, pp. Abstract No. 201. print. Meeting Info.: 44th Annual Meeting of the American Society of Hematology. Philadelphia, PA, USA. December 06-10, 2002. American Society of Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 23 Jul 2003

Last Updated on STN: 23 Jul 2003

AB Thrombotic thrombocytopenic purpura (TTP), a microangiopathic disease, is caused by the persistence of the highly reactive high molecular weight multimers of von Willebrand factor (VWF) due to deficiency of the specific VWF cleaving protease (VWF-CP), ADAMTS13. The acquired form is caused by autoantibodies against VWF-CP, whereas homozygous or compound heterozygous mutations of ADAMTS13 are responsible for recessively inherited TTP. We investigated 83 children with hemolytic and/or thrombocytopenic episodes with or without additional neurologic symptoms or renal failure. The presumed diagnoses were chronic ITP (n=50), TTP (n=8), HUS (n=24) and Evans syndrome (n=1). Eleven patients showed a severe deficiency of VWF-CP (ltoreq5 %). In addition to the 8 patients with a correct diagnosis of TTP, two were first diagnosed to have ITP and one with Evans syndrome. No patient with HUS displayed VWF-CP values <62 %. Antibodies against VWF-CP were found in 4 children. Mutation analysis of the ADAMTS13 gene in the VWF-CP deficient patients by direct sequencing of all 29 exons identified 14 mutations in 7 unrelated individuals. These were three missense mutations, L232Q (n=1), S263C (n=2), P353L (n=2), three nonsense mutations W390X (n=1), R910X (n=2), R1034X (n=1), one two base frameshift deletion 2549-2550delAT (n=1), and one single base frameshift insertion, 4143insA that was the most frequent in our cohort (n=4). Except one homozygous patient with the mutation S263C, all were compound-heterozygous. None of these mutations has been described before, neither were they found on 100 chromosomes of normal controls. These data suggest the diagnosis of hereditary VWF-CP deficiency in one of the patients previously diagnosed with ITP, in the patient with the previous diagnosis of Evans syndrome, and in 5 of the 8 patients with TTP. Molecular analysis of the specific VWF cleaving site by sequencing the VWF A2 domain coding region in the patients with HUS and TTP did not identify any mutation that could confer resistance of VWF to VWF-CP. In

conclusion, the phenotype of TTP in childhood can be rather variable. Besides the classical clinical picture, abortive forms may occur that can delay the identification of patients at risk. Determination of VWF-CP and ADAMTS13 mutation screening is helpful in the differential diagnosis of diseases characterized by recurrent hemolytic and/or thrombocytopenic episodes and to discriminate between the acquired and the hereditary form of TTP.

- L11 ANSWER 29 OF 51 MEDLINE on STN DUPLICATE 16  
 AN 2001349845 MEDLINE  
 DN PubMed ID: 11413376  
 TI Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus.  
 AU Matusan A E; Kelley P G; Pryor M J; Whisstock J C; Davidson A D; Wright P J  
 CS Department of Microbiology and Department of Biochemistry and Molecular Biology, Monash University, PO Box 53, Victoria 3800, Australia.  
 SO The Journal of general virology, (2001 Jul) Vol. 82, No. Pt 7, pp. 1647-56.  
 Journal code: 0077340. ISSN: 0022-1317.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LA English  
 FS Priority Journals  
 EM 200108  
 ED Entered STN: 13 Aug 2001  
 Last Updated on STN: 13 Aug 2001  
 Entered Medline: 9 Aug 2001  
 AB The N-terminal one-third of the NS3 protein of Dengue virus type 2 (DEN-2) complexes with co-factor NS2B to form an active serine proteinase which cleaves the viral polyprotein. To identify sites within NS3 that may interact with NS2B, seven regions within the NS3 proteinase outside the conserved flavivirus enzyme motifs were mutated by alanine replacement. Five sites contained clusters of charged residues and were hydrophilic. Two sites were hydrophobic and highly conserved among flaviviruses. The effects of five mutations on NS2B/3 processing were examined using a COS cell expression system. Four retained significant proteinase activity. Three of these mutations and two more were introduced into genomic-length cDNA and tested for their effects on virus replication. The five mutant viruses showed reduced plaque size and two of the five showed significantly reduced titres. All seven mutations were mapped on the X-ray crystal structure of the DEN-2 NS3 proteinase: three were located at the N terminus and two at the C terminus of the NS2B-binding cleft. Two mutations were at the C terminus of the proteinase domain and one was solvent-exposed. The study demonstrated that charged-to-alanine mutagenesis in the viral proteinase can be used to produce growth-restricted flaviviruses that may be useful in the production of attenuated vaccine strains.
- L11 ANSWER 30 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN  
 AN 2001:317274 BIOSIS  
 DN PREV200100317274  
 TI Persistent inhibition of von Willebrand factor cleaving protease predicts a prolonged course and relapse in patients with thrombotic thrombocytopenic purpura.  
 AU Fijnheer, R. [Reprint author]; Hene, R. J.; Schiphorst, M. E. [Reprint author]; Sixma, J. J. [Reprint author]  
 CS Haematology, University Medical Center Utrecht, Utrecht, Netherlands  
 SO Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 631a. print.

Meeting Info.: 42nd Annual Meeting of the American Society of Hematology.  
San Francisco, California, USA. December 01-05, 2000. American Society of Hematology.

CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
Conference; (Meeting Poster)

LA English

ED Entered STN: 4 Jul 2001

Last Updated on STN: 19 Feb 2002

AB Introduction: Thrombotic thrombocytopenic purpura (TTP) is characterized by the inhibition of a plasma cleaving protease that specifically cleaves von Willebrand factor (vWF cleaving protease), thus reducing its multimeric size. We performed a study in 9 patients with TTP and studied the course of inhibition of vWF cleaving protease activity compared to the clinical outcome. Methods: Plasma from patients with TTP was incubated with recombinant vWF R834Q, a vWF mutant with enhanced sensitivity to the protease. The proteolysis of vWF multimers was analyzed and quantified on Western blot and by collagen binding capacity. The vWF cleaving protease was measured before the start, after 1-2 cycles of plasma exchange and after 3 months. Results: vWF cleaving protease activity was inhibited, before the start of plasma exchange, in all patients (0%, range 0-4%). After initial plasma exchange, the vWF cleaving protease activity was normalized in 3 patients (102%, range 88-144%) and these patients had a quick recovery of peripheral blood counts. Persistent inhibition of vWF cleaving protease (2%, range 0-20%) was correlated with a prolonged course and multiple relapses. Four patients remained to have a complete lack of vWF cleaving protease activity even in period of normal blood counts and no need for plasma exchange. Conclusion: vWF cleaving protease activity predicts the clinical course of TTP and persistent inhibition points at patients with relapsing TTP. On the other hand patients with a totally inhibited vWF cleaving protease can have normal blood counts. We hypothesize that in the etiology of TTP, inhibition of vWF cleaving protease is not enough and a second hit is probably necessary.

L11 ANSWER 31 OF 51 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

AN 1999:500666 SCISEARCH

GA The Genuine Article (R) Number: 212BK

TI Mechanism of endoplasmic reticulum retention of mutant vasopressin precursor caused by a signal peptide truncation associated with diabetes insipidus

AU Spiess M (Reprint)

CS Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland  
(Reprint)

AU Beuret N; Rutishauser J; Bider M D

CS Univ Basel, Bioctr, CH-4056 Basel, Switzerland; Kantonsspital, Dept Med, CH-6000 Luzern 16, Switzerland

CYA Switzerland

SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2 JUL 1999) Vol. 274, No. 27, pp. 18965-18972.

ISSN: 0021-9258.

PB AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.

DT Article; Journal

LA English

REC Reference Count: 42



ED Entered STN: 1999  
 Last Updated on STN: 1999  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Autosomal dominant neurohypophyseal diabetes insipidus is caused by mutations in the gene encoding the vasopressin precursor protein, prepro-vasopressin-neurophysin II. We analyzed the molecular consequences of a mutation (Delta G227) recently identified in a Swiss kindred that destroys the translation initiation codon, In COS-7 cells transfected with the mutant cDNA, translation was found to initiate at an alternative ATG, producing a truncated signal sequence that was functional for targeting and translocation but was not cleaved by signal peptidase, The mutant precursor was completely retained within the endoplasmic reticulum. The uncleaved signal did not affect folding of the neurophysin portion of the precursor, as determined by its protease resistance. However, formation of disulfide-linked aggregates indicated that it interfered with the formation of the disulfide bond in vasopressin, most likely by blocking its insertion into the hormone binding site of neurophysin. Preventing disulfide formation in the vasopressin nonapeptide by mutation of cysteine 6 to serine was shown to be sufficient to cause aggregation and retention. These results indicate that the Delta G227 mutation induces translation of a truncated signal sequence that cannot be cleaved but prevents correct folding and oxidation of vasopressin, thereby causing precursor aggregation and retention in the endoplasmic reticulum.

L11 ANSWER 32 OF 51 MEDLINE on STN DUPLICATE 17  
 AN 1999428772 MEDLINE  
 DN PubMed ID: 10497121  
 TI Second site mutations in the N-terminus of the major capsid protein (VP5) overcome a block at the maturation cleavage site of the capsid scaffold proteins of herpes simplex virus type 1.  
 AU Desai P; Person S  
 CS Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.  
 NC AI33077 (United States NIAID NIH HHS)  
 SO Virology, (1999 Sep 1) Vol. 261, No. 2, pp. 357-66.  
 Journal code: 0110674. ISSN: 0042-6822.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 199910  
 ED Entered STN: 26 Oct 1999  
 Last Updated on STN: 18 Dec 2002  
 Entered Medline: 12 Oct 1999

AB VP5, the major capsid protein of herpes simplex virus type 1 (HSV-1), interacts with the C-terminal residues of the scaffold molecules encoded by the overlapping UL26 and UL26.5 open reading frames. Scaffold molecules are cleaved by a UL26 encoded protease (VP24) as part of the normal capsid assembly process. In this study, residues of VP5 have been identified that alter its interaction with the C-terminal residues of the scaffold proteins. A previously isolated virus (KUL26-610/611) was used that encoded a lethal mutation in the UL26 and UL26.5 open reading frames and required a transformed cell line that expresses these proteins for virus growth. The scaffold maturation cleavage site between amino acids 610 and 611 was blocked by changing Ala-Ser to Glu-Phe, which generated a new EcoRI restriction site. Revertant viruses, that formed small plaques on nontransformed cells, were detected at a frequency of 1:3800. Nine revertants were isolated, and all of them retained the EcoRI site and therefore were due to mutations at a

second site. The second site mutations were extragenic. Using marker-transfer techniques, the mutation in one of the revertants was mapped to the 5' region of the gene encoding VP5. DNA sequence analysis was performed for the N-terminal 571 codons encoding VP5 for all of the revertant viruses. Six of the nine revertants showed a single base pair change that caused an amino acid substitution between residues 30 and 78 of VP5. Three of these were identical and changed Ala to Val at residue 78. The data provide a partial map of residues of VP5 that alter its interaction with scaffold proteins blocked at their normal cleavage site. The yeast two-hybrid system was used as a measure of the interaction between mutant VP5 and scaffold molecules and varied from 11% to nearly 100%, relative to wild-type VP5. One revertant gave no detectable interaction by this assay. The amount of UL26 encoded protease (VP24) in B capsids for KUL26-610/611 and for revertants was 7% and 25%, respectively, relative to the amount in capsids for wild-type virus. The lack of retention of the viral protease in the mutant virus and a fourfold increase for the revertants suggest an additional essential function for VP24 in capsid maturation, and a role in DNA packaging is indicated.

Copyright 1999 Academic Press.

- L11 ANSWER 33 OF 51 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN  
 AN 1999:214234 BIOSIS  
 DN PREV199900214234  
 TI Recovery and half-life of von Willebrand factor (vWF)-cleaving protease after plasma exchange therapy in patients with thrombotic thrombocytopenic purpura (TTP).  
 AU Furlan, M. [Reprint author]; Robles, R. [Reprint author]; Morselli, B.; Sandoz, P.; Lammle, B. [Reprint author]  
 CS Central Hematology Laboratory, University Hospital, Inselspital, Bern, Switzerland  
 SO Annals of Hematology, (1999) Vol. 78, No. SUPPL. 1, pp. A17. print. Meeting Info.: 43rd Annual Meeting of the Society for Thrombosis and Hemostasis. Mannheim, Germany. February 24-27, 1999. Society for Thrombosis and Hemostasis.  
 ISSN: 0939-5555.  
 DT Conference; (Meeting)  
 Conference; Abstract; (Meeting Abstract)  
 LA English  
 ED Entered STN: 26 May 1999  
 Last Updated on STN: 26 May 1999
- L11 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 1998:485878 CAPLUS  
 DN 129:227431  
 OREF 129:46169a,46172a  
 TI Engineering the S1' subsite of trypsin: Design of a protease which cleaves between dibasic residues  
 AU Kurth, Torsten; Grahn, Sibylla; Thormann, Michael; Ullmann, Dirk; Hofmann, Hans-Joerg; Jakubke, Hans-Dieter; Hedstrom, Lizbeth  
 CS Department of Biochemistry, Brandeis University, Waltham, MA, 02454, USA  
 SO Biochemistry (1998), 37(33), 11434-11440  
 CODEN: BICHAW; ISSN: 0006-2960  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Here, trypsin was redesigned by protein engineering into a site-specific protease which hydrolyzes peptides between dibasic residues. Trypsin normally exhibits high S1 specificity for Arg and Lys residues. However, the S1' specificity of trypsin is very broad, with only a slight

preference for hydrophobic residues in P1'. Here, the authors replaced Lys-60 with Glu and Asp to introduce a high specificity for basic residues into the S1' site of trypsin. Both mutations caused a dramatic increase in S1' specificity for Arg and Lys as measured by acyl transfer reactions. In mutant K60E, the preference for Arg increased 70-fold, whereas the preference for P1'-Lys increased 12-fold. In contrast, the preferences for other P1' residues either decreased slightly or remained the same. Thus, K60E prefers P1'-Arg over most other P1' residues by 2 orders of magnitude. Similar results were obtained when P1' specificity was measured in peptide cleavage assays. K60D exhibited an S1' specificity profile very similar to that of K60E, although the P1'-Arg preference was reduced by a factor of 2.5. Mol. modeling studies suggested that the high S1' specificity for Arg in K60E may be due to the formation of a salt bridge between Glu-60 and P1'-Arg of the substrate.

OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 35 OF 51 MEDLINE on STN DUPLICATE 18  
 AN 1998362178 MEDLINE  
 DN PubMed ID: 9696869  
 TI Molecular characterization of proteolytic processing of the Pol proteins of human foamy virus reveals novel features of the viral protease.  
 AU Pfrepper K I; Rackwitz H R; Schnolzer M; Heid H; Lochelt M; Flugel R M  
 CS Abteilungen Retroviral Gene Expression, Research Program Applied Tumorvirology, German Cancer Research Center, 69009 Heidelberg, Federal Republic of Germany.  
 SO Journal of virology, (1998 Sep) Vol. 72, No. 9, pp. 7648-52.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC110030.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199809  
 ED Entered STN: 25 Sep 1998  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 16 Sep 1998  
 AB Spumaviruses, or foamy viruses, express a pol-specific transcript that codes for a Pol polyprotein that consists of the protease, reverse transcriptase, ribonuclease H, and the integrase domains. To delineate the proteolytic cleavage sites between the Pol subdomains, recombinant human foamy virus (HFV) Pol proteins were expressed, purified by affinity chromatography, and subjected to either HFV protease assays or autocatalytic processing. In control experiments, HFV protease-deficient mutant proteins in which the active site Asp was replaced by an Ala residue were used to rule out unspecific processing by nonviral proteases. Specific proteolytic cleavage products were isolated, and the cleavage sites were analyzed by amino acid sequencing. Peptides spanning the resulting cleavage sites were chemically synthesized and assayed with HFV protease, and the cleaved peptides were subjected to mass spectrometry. The cleavage site sequences obtained were in complete agreement with the amino-terminal sequences from amino acid sequencing of authentic cleavage products of the HFV Pol proteins. Analysis by fast-protein liquid chromatography of a short version of the active HFV protease revealed that the enzyme predominantly formed dimeric molecules.

L11 ANSWER 36 OF 51 MEDLINE on STN DUPLICATE 19  
 AN 1998422118 MEDLINE  
 DN PubMed ID: 9751498

TI A protease-resistant form of insulin-like growth factor (IGF) binding  
 protein 4 inhibits IGF-1 actions.  
 AU Rees C; Clemmons D R; Horvitz G D; Clarke J B; Busby W H  
 CS Department of Medicine, University of North Carolina School of Medicine,  
 Chapel Hill 27599-7170, USA.  
 NC HL-56850 (United States NHLBI NIH HHS)  
 SO Endocrinology, (1998 Oct) Vol. 139, No. 10, pp. 4182-8.  
 Journal code: 0375040. ISSN: 0013-7227.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199810  
 ED Entered STN: 20 Oct 1998  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 8 Oct 1998  
 AB Smooth muscle cells (SMC) secrete a serine protease that  
 cleaves insulin-like growth factor (IGF) binding protein (IGFBP)-4  
 into fragments that have low affinity for IGF-1. When IGFBP-4 is added to  
 monolayer cultures of cell types that do not secrete this protease, IGF-1  
 stimulation of DNA synthesis is significantly inhibited. In contrast, if  
 cell types that secrete this protease are used, IGFBP-4 is a much less  
 potent inhibitor. These studies were conducted to determine whether  
 proteolysis of IGFBP-4 accounted for its reduced capacity to inhibit  
 IGF-1-stimulated DNA synthesis. The cleavage site in IGFBP-4 that the SMC  
 protease uses was determined to be lysinel20, histidinel21. A  
 protease-resistant mutant form of IGFBP-4 was prepared,  
 expressed, purified, and tested for biologic activity using porcine SMC  
 cultures. Addition of the protease-resistant mutant  
 resulted in inhibition of DNA and cell migration responses to IGF-1. The  
 inhibition was concentration dependent and was maximal when 500 ng/ml (20  
 nM) of the mutant was added with 20 ng/ml (2.8 nM) of IGF-1. When the  
 mutant was added in the absence of IGF-1, it had no activity. The results  
 show that cleavage of IGFBP-4 at lysinel20, histidinel21 results in  
 inactivation of the ability of IGFBP-4 to bind to IGF-1. Creation of a  
 mutant form of IGFBP-4 that was not cleaved by the  
 protease resulted in inhibition of IGF-1-stimulated actions. The  
 results suggest that IGFBP-4 can act as a potent inhibitor of the anabolic  
 effects of IGF-1 and that the variables that regulate protease activity  
 may indirectly regulate IGF-1 actions.

L11 ANSWER 37 OF 51 MEDLINE on STN DUPLICATE 20  
 AN 1996256783 MEDLINE  
 DN PubMed ID: 8676497  
 TI Characterization of the rubella virus nonstructural protease domain and  
 its cleavage site.  
 AU Chen J P; Strauss J H; Strauss E G; Frey T K  
 CS Department of Biology, Georgia State University, Atlanta, Georgia, 30303,  
 USA.  
 NC AI10793 (United States NIAID NIH HHS)  
 AI21389 (United States NIAID NIH HHS)  
 SO Journal of virology, (1996 Jul) Vol. 70, No. 7, pp. 4707-13.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC190407.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 199608

ED Entered STN: 22 Aug 1996  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 15 Aug 1996

AB The region of the rubella virus nonstructural open reading frame that contains the papain-like cysteine protease domain and its cleavage site was expressed with a Sindbis virus vector. Cys-1151 has previously been shown to be required for the activity of the protease (L. D. Marr, C.-Y. Wang, and T. K Frey, *Virology* 198:586-592, 1994). Here we show that His-1272 is also necessary for protease activity, consistent with the active site of the enzyme being composed of a catalytic dyad consisting of Cys-1151 and His-1272. By means of radiochemical amino acid sequencing, the site in the polyprotein cleaved by the nonstructural protease was found to follow Gly-1300 in the sequence Gly-1299-Gly-1300-Gly-1301. Mutagenesis studies demonstrated that change of Gly-1300 to alanine or valine abrogated cleavage. In contrast, Gly-1299 and Gly-1301 could be changed to alanine with retention of cleavage, but a change to valine abrogated cleavage. Coexpression of a construct that contains a cleavage site mutation (to serve as a protease) together with a construct that contains a protease mutation (to serve as a substrate) failed to reveal trans cleavage. Coexpression of wild-type constructs with protease-mutant constructs also failed to reveal trans cleavage, even after extended in vitro incubation following lysis. These results indicate that the protease functions only in cis, at least under the conditions tested.

L11 ANSWER 38 OF 51 MEDLINE on STN DUPLICATE 21  
 AN 1996256740 MEDLINE  
 DN PubMed ID: 8676454  
 TI Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids.  
 AU Robertson B J; McCann P J 3rd; Matusick-Kumar L; Newcomb W W; Brown J C; Colonno R J; Gao M  
 CS Department of Virology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA.  
 SO *Journal of virology*, (1996 Jul) Vol. 70, No. 7, pp. 4317-28.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC190364.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 199608  
 ED Entered STN: 22 Aug 1996  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 15 Aug 1996

AB The herpes simplex virus type 1 (HSV-1) protease (Pra) and related proteins are involved in the assembly of viral capsids and virion maturation. Pra is a serine protease, and the active-site residue has been mapped to amino acid (aa) 129 (Ser). This 635-aa protease, encoded by the UL26 gene, is autoproteolytically processed at two sites, the release (R) site between amino acid residues 247 and 248 and the maturation (M) site between residues 610 and 611. When the protease cleaves itself at both sites, it releases Nb, the catalytic domain (N0), and the C-terminal 25 aa. ICP35, a substrate of the HSV-1 protease, is the product of the UL26.5 gene. As it is translated from a Met codon within the UL26 gene, ICP35 cd are identical to the C-terminal 29-aa sequence of the protease and are trans cleaved at an identical C-terminal site to generate ICP35 e,f and a 25-aa peptide. Only fully processed Pra (N0 and Nb) and ICP35 (ICP35 e,f) are present in B capsids, which are believed to be precursors of

mature virions. Using an R-site mutant A247S virus, we have recently shown that this mutant protease retains enzymatic activity but fails to support viral growth, suggesting that the release of N0 is required for viral replication. Here we report that another mutant protease, with an amino acid substitution (Ser to Cys) at the active site, can complement the A247S mutant but not a protease deletion mutant. Cell lines expressing the active-site mutant protease were isolated and shown to complement the A247S mutant at the levels of capsid assembly, DNA packaging, and viral growth. Therefore, the complementation between the R-site mutant and the active-site mutant reconstituted wild-type Pra function. One feature of this intragenic complementation is that following sedimentation of infected-cell lysates on sucrose gradients, both N-terminally unprocessed and processed proteases were isolated from the fractions where normal B capsids sediment, suggesting that proteolytic processing occurs inside capsids. Our results demonstrate that the HSV-1 protease has distinct functional domains and some of these functions can complement in trans.

L11 ANSWER 39 OF 51 MEDLINE on STN DUPLICATE 22  
 AN 1996068694 MEDLINE  
 DN PubMed ID: 7479877  
 TI Shared functions in vivo of a glycosyl-phosphatidylinositol-linked aspartyl protease, Mkc7, and the proprotein processing protease Kex2 in yeast.  
 AU Komano H; Fuller R S  
 CS Department of Biochemistry, Stanford University School of Medicine, CA 94305-5307, USA.  
 NC GM39697 (United States NIGMS NIH HHS)  
 SO Proceedings of the National Academy of Sciences of the United States of America, (1995 Nov 7) Vol. 92, No. 23, pp. 10752-6.  
 Journal code: 7505876. ISSN: 0027-8424.  
 Report No.: NLM-PMC40690.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 OS GENBANK-U14733  
 EM 199512  
 ED Entered STN: 24 Jan 1996  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 21 Dec 1995  
 AB The MKC7 gene was isolated as a multicopy suppressor of the cold-sensitive growth phenotype of a yeast kex2 mutant, which lacks the protease that cleaves pro-alpha-factor and other secretory proproteins at pairs of basic residues in a late Golgi compartment in yeast. MKC7 encodes an aspartyl protease most closely related to product of the YAP3 gene, a previously isolated multicopy suppressor of the pro-alpha-factor processing defect of a kex2 null. Multicopy MKC7 suppressed the alpha-specific mating defect of a kex2 null as well as multicopy YAP3 did, but multicopy YAP3 was a relatively weak suppressor of kex2 cold sensitivity. Overexpression of MKC7 resulted in production of a membrane-associated proteolytic activity that cleaved an internally quenched fluorogenic peptide substrate on the carboxyl side of a Lys-Arg site. Treatment with phosphatidylinositol-specific phospholipase C shifted Mkc7 activity from the detergent to the aqueous phase in a Triton X-114 phase separation, indicating that membrane attachment of Mkc7 is mediated by a glycosyl-phosphatidylinositol anchor. Although disruption of MKC7 or YAP3 alone resulted in no observable

phenotype, *mkc7 yap3* double disruptants exhibited impaired growth at 37 degrees C. Disruption of *MKC7* and *YAP3* in a *kex2* null mutant resulted in profound temperature sensitivity and more generalized cold sensitivity. The synergism of *mkc7*, *yap3*, and *kex2* null mutations argues that *Mkc7* and *Yap3* are authentic processing enzymes whose functions overlap those of *Kex2* in vivo.

L11 ANSWER 40 OF 51 MEDLINE on STN DUPLICATE 23  
 AN 1995181426 MEDLINE  
 DN PubMed ID: 7533161  
 TI Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants.  
 AU Conover C A; Durham S K; Zapf J; Masiarz F R; Kiefer M C  
 CS Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.  
 NC DK-07352 (United States NIDDK NIH HHS)  
 DK-43258 (United States NIDDK NIH HHS)  
 SO The Journal of biological chemistry, (1995 Mar 3) Vol. 270, No. 9, pp. 4395-400.  
 Journal code: 2985121R. ISSN: 0021-9258.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals  
 EM 199504  
 ED Entered STN: 19 Apr 1995  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 5 Apr 1995  
 AB Cultured human fibroblasts and osteoblast-like cells secrete an insulin-like growth factor (IGF)-dependent protease that cleaves IGF-binding protein-4 (IGFBP-4) into two fragments of approximately 18 and 14 kDa. Edman degradation of the isolated proteins established the amino termini of the reaction products. Sequence analysis of the 14-kDa carboxyl-terminal half of IGFBP-4 suggested cleavage after methionine at position 135 of the mature protein. Four variant IGFBP-4 molecules with single amino acid substitutions around this cleavage site were constructed and expressed. Wild-type and mutant IG-FBPs-4 bound IGF-I and IGF-II with equivalent affinities and, in the intact state, were equally effective inhibitors of IGF-I action. However, the IGFBP-4 mutants were relatively resistant to IGF-dependent proteolysis. A 5-6-h incubation in human fibroblast conditioned medium in the presence of IGF-II was sufficient for near total hydrolysis of wild-type IGFBP-4, whereas the mutant IGFBPs-4 were only minimally affected at this time. After a 24-h incubation with IGF-II, all mutant IGFBPs-4 showed extensive proteolysis, generating 18- and 14-kDa fragments. Pre-exposure of human fibroblasts in serum-free conditioned medium to IGF-II for 5 h potentiated subsequent IGF-I stimulation of DNA synthesis. When added with IGF-II, the protease-resistant mutant IG-FBPs-4, but not wild-type IGFBP-4, suppressed IGF-II enhancement of IGF-I-stimulated DNA synthesis. These biological studies suggest that the IGFBP-4/IGFBP-4 protease system may play a role modulating local cellular response to IGF-I.

L11 ANSWER 41 OF 51 MEDLINE on STN DUPLICATE 24  
 AN 1995264461 MEDLINE  
 DN PubMed ID: 7745718  
 TI Assembly of the herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes.

AU Thomsen D R; Newcomb W W; Brown J C; Homa F L  
 CS Upjohn Company, Kalamazoo, Michigan 49001, USA.  
 SO Journal of virology, (1995 Jun) Vol. 69, No. 6, pp. 3690-703.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC189085.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199506  
 ED Entered STN: 21 Jun 1995  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 13 Jun 1995  
 AB Herpes simplex virus type 1 (HSV-1) intermediate capsids are composed of seven proteins, VP5, VP19C, VP21, VP22a, VP23, VP24, and VP26, and the genes that encode these proteins, UL19, UL38, UL26, UL26.5, UL18, UL26, and UL35, respectively. The UL26 gene encodes a protease that cleaves itself and the product of the UL26.5 gene at a site (M site) 25 amino acids from the C terminus of these two proteins. In addition, the protease cleaves itself at a second site (R site) between amino acids 247 and 248. Cleavage of the UL26 protein gives rise to the capsid proteins VP21 and VP24, and cleavage of the UL26.5 protein gives rise to the capsid protein VP22a. Previously we described the production of HSV-1 capsids in insect cells by infecting the cells with recombinant baculoviruses expressing the six capsid genes (D. R. Thomsen, L. L. Roof, and F. L. Homa, J. Virol. 68:2442-2457, 1994). Using this system, we demonstrated that the products of the UL26 and/or UL26.5 genes are required as scaffolds for assembly of HSV-1 capsids. To better understand the functions of the UL26 and UL26.5 proteins in capsid assembly, we constructed baculoviruses that expressed altered UL26 and UL26.5 proteins. The ability of the altered UL26 and UL26.5 proteins to support HSV-1 capsid assembly was then tested in insect cells. Among the specific mutations tested were (i) deletion of the C-terminal 25 amino acids from the proteins coded for by the UL26 and UL26.5 genes; (ii) mutation of His-61 of the UL26 protein, an amino acid required for protease activity; and (iii) mutation of the R cleavage site of the UL26 protein. Analysis of the capsids formed with wild-type and mutant proteins supports the following conclusions: (i) the C-terminal 25 amino acids of the UL26 and UL26.5 proteins are required for capsid assembly; (ii) the protease activity associated with the UL26 protein is not required for assembly of morphologically normal capsids; and (iii) the uncleaved forms of the UL26 and UL26.5 proteins are employed in assembly of 125-nm-diameter capsids; cleavage of these proteins occurs during or subsequent to capsid assembly. Finally, we carried out in vitro experiments in which the major capsid protein VP5 was mixed with wild-type or truncated UL26.5 protein and then precipitated with a VP5-specific monoclonal antibody. (ABSTRACT TRUNCATED AT 400 WORDS)

L11 ANSWER 42 OF 51 MEDLINE on STN DUPLICATE 25  
 AN 1995264435 MEDLINE  
 DN PubMed ID: 7745693  
 TI Foot-and-mouth disease virus Lb proteinase can stimulate rhinovirus and enterovirus IRES-driven translation and cleave several proteins of cellular and viral origin.  
 AU Ziegler E; Borman A M; Kirchweger R; Skern T; Kean K M  
 CS Unite de Virologie Moleculaire (CNRS URA 1966), Institut Pasteur, Paris, France.  
 SO Journal of virology, (1995 Jun) Vol. 69, No. 6, pp. 3465-74.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC189059.  
 CY United States



DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LA English  
 FS Priority Journals  
 EM 199506  
 ED Entered STN: 21 Jun 1995  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 13 Jun 1995

AB Rhinovirus and enterovirus 2A proteinases stimulate translation initiation driven from the cognate internal ribosome entry segment (IRES) (S. J. Hambidge and P. Sarnow, Proc. Natl. Acad. Sci. USA 89:10272-10276, 1992; H.-D. Liebig, E. Ziegler, R. Yan, K. Hartmuth, H. Klump, H. Kowalski, D. Blaas, W. Sommergruber, L. Frasel, B. Lamphear, R. Rhoads, E. Kuechler, and T. Skern, Biochemistry 32:7581-7588, 1993). Given the functional similarities between the foot-and-mouth disease virus (FMDV) L proteinase and these 2A proteinases (autocatalytic excision from the nascent viral polyprotein and cleavage of eIF-4 gamma), we investigated whether the FMDV L proteinase would also be able to stimulate translation initiation. We found that purified recombinant FMDV Lb proteinase could stimulate in vitro translation driven from a rhinovirus or enterovirus IRES by 5- to 10-fold. In contrast, stimulation of translation initiation on a cardiovirus IRES by this proteinase was minimal, and stimulation of translation driven from the cognate FMDV IRES could not be evidenced. Studies using an inhibitor or a mutant Lb proteinase indicated that stimulation of IRES-driven translation is mediated via proteolysis of some cellular component(s). Our studies also demonstrated that the Lb proteinase is capable of stimulating initiation of translation on an uncapped cellular message. Unexpectedly, and in contrast to the 2A proteinases, the Lb proteinase specifically cleaved the products of the two reporter genes used in this study: *Xenopus laevis* cyclin B2 and influenza virus NS. Therefore, we also set out to investigate the requirements for substrate recognition by the Lb proteinase. Purified recombinant Lb proteinase recognized at least one mengovirus polypeptide and specifically cleaved human cyclin A and poliovirus replicase-related polypeptides. In the latter case, the site(s) of cleavage was located within the N-terminal part of polypeptide 3D. Sequence comparisons revealed no significant primary sequence similarities between the target proteins and the two sites already known to be recognized by the FMDV L proteinase.

L11 ANSWER 43 OF 51 MEDLINE on STN DUPLICATE 26  
 AN 1994197861 MEDLINE  
 DN PubMed ID: 8148011  
 TI Proteolysis in heterocyst-forming cyanobacteria: characterization of a further enzyme with trypsin-like specificity, and of a prolyl endopeptidase from *Anabaena variabilis*.  
 AU Strohmeier U; Gerdes C; Lockau W  
 CS Institut fur Botanik der Universitat, Regensburg, Bundesrepublik Deutschland.  
 SO Zeitschrift fur Naturforschung. C, Journal of biosciences, (1994 Jan-Feb) Vol. 49, No. 1-2, pp. 70-8.  
 Journal code: 8912155. ISSN: 0939-5075.  
 CY GERMANY: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LA English  
 FS Priority Journals  
 EM 199405  
 ED Entered STN: 23 May 1994  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 11 May 1994

AB Soluble extracts of the cyanobacterium *Anabaena variabilis* ATCC 29413 and an engineered mutant that lacks an intracellular protease cleaving after Lys and Arg (Maldener, Lockau, Cai, and Wolk, Mol. Gen. Genet. 225, 113-120 (1991)) were separated by ion exchange chromatography, and protease profiles determined using azocasein, N alpha-benzoyl-D,L-arginine-4-nitroanilide and N-carbobenzoxy-glycyl-L-proline-4-nitroanilide as substrates. A second enzyme cleaving at the carboxyl side of lysine and arginine, and a prolyl endopeptidase were detected, enriched and characterized. Both proteolytic enzymes appear to be located in the periplasm.

L11 ANSWER 44 OF 51 MEDLINE on STN DUPLICATE 27  
AN 1994285789 MEDLINE  
DN PubMed ID: 7516997  
TI A conserved *Streptococcus pyogenes* extracellular cysteine protease cleaves human fibronectin and degrades vitronectin.  
AU Kapur V; Topouzis S; Majesky M W; Li L L; Hamrick M R; Hamill R J; Patti J M; Musser J M  
CS Department of Pathology, Baylor College of Medicine, Houston, Texas 77030.  
NC HL-47655 (United States NHLBI NIH HHS)  
SO Microbial pathogenesis, (1993 Nov) Vol. 15, No. 5, pp. 327-46.  
Journal code: 8606191. ISSN: 0882-4010.  
CY ENGLAND: United Kingdom  
DT (COMPARATIVE STUDY)  
Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)  
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
LA English  
FS Priority Journals  
OS GENBANK-L26125; GENBANK-L26126; GENBANK-L26127; GENBANK-L26128;  
GENBANK-L26129; GENBANK-L26130; GENBANK-L26131; GENBANK-L26132;  
GENBANK-L26133; GENBANK-L26134; GENBANK-L26135; GENBANK-L26136;  
GENBANK-L26137; GENBANK-L26138; GENBANK-L26139; GENBANK-L26140;  
GENBANK-L26141; GENBANK-L26142; GENBANK-L26143; GENBANK-L26144;  
GENBANK-L26145; GENBANK-L26146; GENBANK-L26147; GENBANK-L26148;  
GENBANK-L26149; GENBANK-L26150; GENBANK-L26151; GENBANK-L26152;  
GENBANK-L26153; GENBANK-L26154; +  
EM 199407  
ED Entered STN: 10 Aug 1994  
Last Updated on STN: 3 Mar 2000  
Entered Medline: 28 Jul 1994  
AB *Streptococcus pyogenes* secretes an extracellular cysteine protease that cleaves human interleukin 1 beta precursor to form biologically active IL-1 beta, a major cytokine mediating inflammation and shock. To further investigate the potential role of the cysteine protease in host-parasite interactions, the enzyme was purified to apparent homogeneity and tested for ability to degrade several human extracellular matrix proteins. Purified protease cleaved fibronectin, apparently at specific sites, and rapidly degraded vitronectin. In contrast, the protease did not have substantial activity against laminin. The cysteine protease also cleaved fibronectin from human umbilical vein endothelial cells grown in vitro. Allelic variation in the cysteine protease structural gene was studied in 67 strains expressing 39 M protein serotypes and five provisional M serologic types, and representing 50 phylogenetically distinct clones identified by multilocus enzyme electrophoresis. The gene is well conserved and allelic variation is due solely to accumulation of point mutations. Based on predicted amino acid sequences, one mature cysteine protease variant would be made by clones expressing serotypes M2, M3, M4, M5, M6, M9, M10, M11, M12, M14, M18, M22, M23, M25, M27, M41, M49, M56, M59, two provisional M types, and two clones

non-typeable for M protein. Moreover, 33 of the 39 speB alleles identified encode one of three mature protease variants that differ from one another at only one or two amino acids clustered in a ten-amino acid region. All 39 alleles, and virtually all strains, encode a product that reacts with polyclonal antisera specific for purified cysteine protease. No compelling evidence was found for a primitive differentiation of the speB gene into two distinct classes, as has been proposed for M protein, opacity factor phenotype, and vir regulon architecture. The results demonstrate that the cysteine protease is well conserved in natural populations of *S. pyogenes*, provide additional evidence that this enzyme is involved in host-parasite interactions, and suggest that the protease plays a role in bacterial dissemination, colonization, and invasion, and inhibition of wound healing.

L11 ANSWER 45 OF 51 MEDLINE on STN DUPLICATE 28  
 AN 1992292244 MEDLINE  
 DN PubMed ID: 1602542  
 TI Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage.  
 AU Sommerfelt M A; Petteway S R Jr; Dreyer G B; Hunter E  
 CS Department of Microbiology, University of Alabama, Birmingham 35294.  
 NC CA 27834 (United States NCI NIH HHS)  
 SO Journal of virology, (1992 Jul) Vol. 66, No. 7, pp. 4220-7.  
 Journal code: 0113724. ISSN: 0022-538X.  
 Report No.: NLM-PMC241225.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)  
 LA English  
 FS Priority Journals; AIDS  
 EM 199207  
 ED Entered STN: 24 Jul 1992  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 10 Jul 1992  
 AB Mason-Pfizer monkey virus (M-PMV) is the prototype type D retrovirus which preassembles immature intracytoplasmic type A particles within the infected cell cytoplasm. Intracytoplasmic type A particles are composed of uncleaved polyprotein precursors which upon release are cleaved by the viral proteinase to their constituent mature proteins. This results in a morphological change in the virion described as maturation. We have investigated the role of the viral proteinase in virus maturation and infectivity by inhibiting the function of the enzyme through mutagenesis of the proteinase gene and by using peptide inhibitors originally designed to block human immunodeficiency virus type 1 proteinase activity. Mutation of the active-site aspartic acid, Asp-26, to asparagine abrogated the activity of the M-PMV proteinase but did not affect the assembly of noninfectious, immature virus particles. In mutant virions, the transmembrane glycoprotein (TM) of M-PMV, initially synthesized as a cell-associated gp22, is not cleaved to gp20, as is observed with wild-type virions. This demonstrates that the viral proteinase is responsible for this cleavage event. Hydroxyethylene isostere human immunodeficiency virus type 1 proteinase inhibitors were shown to block M-PMV proteinase cleavage of the TM glycoprotein and Gag-containing precursors in a dose-dependent manner. The TM cleavage event was more sensitive than cleavage of the Gag precursors to inhibition. The infectivity of treated particles was reduced significantly, but experiments showed that inhibition of precursor and TM cleavage may be at least partially reversible. These results demonstrate that the M-PMV aspartyl proteinase is activated in released virions and that the hydroxyethylene isostere proteinase inhibitors used in this study exhibit a broad spectrum of antiretroviral activity.

L11 ANSWER 46 OF 51 MEDLINE on STN DUPLICATE 29  
 AN 1992237326 MEDLINE  
 DN PubMed ID: 1570342  
 TI A genetic system for studying the activity of a proteolytic enzyme.  
 AU Dasmahapatra B; DiDomenico B; Dwyer S; Ma J; Sadowski I; Schwartz J  
 CS Antiviral Chemotherapy, Schering-Plough Research Institute, Bloomfield, NJ 07003.  
 SO Proceedings of the National Academy of Sciences of the United States of America, (1992 May 1) Vol. 89, No. 9, pp. 4159-62.  
 Journal code: 7505876. ISSN: 0027-8424.  
 Report No.: NLM-PMC525652.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199205  
 ED Entered STN: 12 Jun 1992  
 Last Updated on STN: 29 Jan 1996  
 Entered Medline: 28 May 1992  
 AB We describe a genetic system for monitoring the activity of a specific proteolytic enzyme by taking advantage of the properties of the yeast transcriptional activator GAL4. The GAL4 protein contains two separable and functionally essential domains: the amino-terminal DNA binding domain and the carboxyl-terminal transcriptional activating domain. We constructed two hybrid proteins by inserting between the DNA binding domain and the activation domain of GAL4 either (i) a self-cleaving protease (3C protease of a picornavirus, coxsackievirus B3) or (ii) a mutant form of the protease that is unable to cleave. We show that, although the hybrid protein containing the mutant protease activates transcription of GAL1-lacZ reporter gene, the hybrid protein bearing the wild-type protease is proteolytically cleaved and fails to activate transcription. Our approach to monitor the proteolytic activity could be used to develop simple genetic systems to study other proteases.

L11 ANSWER 47 OF 51 MEDLINE on STN DUPLICATE 30  
 AN 1988251412 MEDLINE  
 DN PubMed ID: 3289538  
 TI Mutant isolation and cloning of the gene encoding protease VII from Escherichia coli.  
 AU Sugimura K  
 CS Suntory Bio Pharma Tech Center, Gunma, Japan.  
 SO Biochemical and biophysical research communications, (1988 Jun 16) Vol. 153, No. 2, pp. 753-9.  
 Journal code: 0372516. ISSN: 0006-291X.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198807  
 ED Entered STN: 8 Mar 1990  
 Last Updated on STN: 8 Mar 1990  
 Entered Medline: 22 Jul 1988  
 AB A mutant of Escherichia coli lacking protease VII, the outer membrane-associated protease which specifically cleaves paired basic residues (1), was isolated by using N-methyl-N'-nitro-N-nitrosoguanidine treatment. The mutant exhibited no significant change as for its growth rate and microscopic feature compared with wild cells. The gene encoding protease VII was cloned by using

complementation analysis of protease VII (-) mutation.  
 The minicell experiment showed that the gene encoded a putative precursor protein of 38,000 Mr which was processed into a protein of 36,000 Mr suggesting the presence of a signal peptide on the putative precursor.

- L11 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 1987:82679 CAPLUS  
 DN 106:82679  
 OREF 106:13549a,13552a  
 TI Cleavage site mutant as a potential vaccine  
 AU Homma, Morio  
 CS Sch. Med., Kobe Univ., Kobe, 650, Japan  
 SO Concepts Viral Pathog. (1986), Volume 2, 388-93. Editor(s): Notkins, Abner Louis; Oldstone, Michael B. A. Publisher: Springer, New York, N. Y. CODEN: 52MXA4  
 DT Conference; General Review  
 LA English  
 AB A review with 21 refs. Paramyxoviruses and influenza viruses become activated and replicate in multiple cycles when the envelope glycoprotein of the virus is cleaved by a host protease. In the absence of protease, the replication is limited to a single cycle. A protease activation mutant of Sendai virus was obtained, whose replication is restricted to a single cycle in the lung of mice, but which nevertheless, induces immunity. The availability of such mutants for vaccines, their strengths and limitations are discussed.
- L11 ANSWER 49 OF 51 MEDLINE on STN DUPLICATE 31  
 AN 1983290793 MEDLINE  
 DN PubMed ID: 6350278  
 TI Temperature-sensitive prolipoprotein signal peptidase in an Escherichia coli mutant: use of the mutant for an efficient and convenient assay system.  
 AU Yamagata H  
 SO Journal of biochemistry, (1983 Jun) Vol. 93, No. 6, pp. 1509-15. Journal code: 0376600. ISSN: 0021-924X.  
 CY Japan  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198310  
 ED Entered STN: 19 Mar 1990  
 Last Updated on STN: 3 Mar 2000  
 Entered Medline: 8 Oct 1983  
 AB Escherichia coli mutant Y815 accumulates the precursor of lipoprotein (prolipoprotein) in its envelope. The accumulated prolipoprotein could be chased to mature lipoprotein at 30 degrees C but not at 60 degrees C (Yamagata, H., Ippolito, C., Inukai, M., & Inouye, M. (1982) J. Bacteriol. 152, 1163). When the envelope fraction prepared from the mutant was mixed with the envelope fraction prepared from wild-type E. coli cells and incubated at 60 degrees C in the presence of Triton X-100, the prolipoprotein in the mutant envelope fraction was cleaved rapidly to mature lipoprotein. The cleavage was dependent on the addition of wild-type envelope fraction and Triton X-100 to the reaction mixture. This indicated that the prolipoprotein accumulated in the mutant envelope is a good substrate for the signal peptidase which cleaves the signal peptide from the prolipoprotein, and hence the accumulation of prolipoprotein was due to lack of the signal peptidase in the mutant. The optimum concentration of Triton X-100 for the cleavage of the prolipoprotein in the above in vitro system was 0.05 to 0.1% (v/v) at a wild-type envelope concentration of 0.35 mg protein/ml. Prolipoprotein accumulated in wild-type cells on

treatment with globomycin, a specific inhibitor of the signal peptidase, was also cleaved to mature lipoprotein under the same conditions. Triton X-100 was shown to solubilize the signal peptidase from the envelope fraction. The cleavage of the prolipoprotein was rapid and complete in the in vitro system described here, which provides an efficient and convenient assay system for the solubilized signal peptidase for prolipoprotein.

L11 ANSWER 50 OF 51 MEDLINE on STN DUPLICATE 32

AN 1976005412 MEDLINE

DN PubMed ID: 51020

TI Proteinase C (carboxypeptidase Y) mutant of yeast.

AU Wolf D H; Fink G R

SO Journal of bacteriology, (1975 Sep) Vol. 123, No. 3, pp. 1150-6.

Journal code: 2985120R. ISSN: 0021-9193.

Report No.: NLM-PMC235840.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 197512

ED Entered STN: 13 Mar 1990

Last Updated on STN: 13 Mar 1990

Entered Medline: 4 Dec 1975

AB A mutant of yeast lacking proteinase C

(carboxypeptidase Y) activity has been found by using a histochemical stain to screen mutagenized colonies. This defect segregates 2:2 in meiotic tetrads. Cell extracts lacked the esterolytic, amidase, and proteolytic activities associated with proteinase C. The absence of proteinase C does not affect mitotic growth and has no obvious effect on the formation of viable ascospores or meiotic segregation. The mutant grows on peptides known to be cleaved by proteinase C in vitro. This finding is consistent with the idea that other enzymes exist in vivo with overlapping substrate specificities.

L11 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1971:39504 CAPLUS

DN 74:39504

OREF 74:6341a,6344a

TI Peptidases in Escherichia coli K-12 capable of cleaving lysine homopeptides

AU Sussman, Arthur J.; Gilvarg, Charles

CS Dep. Biochem. Sci., Princeton Univ., Princeton, NJ, USA

SO Journal of Biological Chemistry (1970), 245(24), 6518-24

CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

AB The peptidases present in E. coli K-12 that can cleave lysine oligopeptides were characterized to establish a system in which one could examine questions relating to peptidase specificity, function, and regulation. As an aid to this study, a mutant with diminished peptidase activity was isolated with the use of the reduced ability to cleave tryllysine as a screening procedure. In this simplified system, the remaining enzymic capacity to cleave lysine homopeptides was then characterized. On the basis of substrate specificities and cofactor requirements as well as resolution of the enzymes by ion exchange and Sephadex chromatog., it was shown that the mutant contains the following lysine peptidases: (a) a Co<sup>2+</sup> dependent peptidase capable of splitting dilysine, (b) an EDTA sensitive peptidase specific for tryllysine, and (c) an endopeptidase that can cleave tetralysine but has no activity toward di- or tryllysine. The parental K-12 strain contains, in addition to these 3

activities, a metal independent peptidase capable of  
cleaving all 3 lysine peptides.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=> S (protease or proteinase or peptidase) (4A) (substrate binding)  
L12 483 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (SUBSTRATE BINDING)

=> s l11 and l12  
L13 1 L11 AND L12

=> d l13 bib ab

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1998:485878 CAPLUS

DN 129:227431

OREF 129:46169a,46172a

TI Engineering the S1' subsite of trypsin: Design of a protease which cleaves  
between dibasic residues

AU Kurth, Torsten; Grahn, Sibylla; Thormann, Michael; Ullmann, Dirk; Hofmann,  
Hans-Joerg; Jakubke, Hans-Dieter; Hedstrom, Lizbeth

CS Department of Biochemistry, Brandeis University, Waltham, MA, 02454, USA

SO Biochemistry (1998), 37(33), 11434-11440

CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

AB Here, trypsin was redesigned by protein engineering into a site-specific  
protease which hydrolyzes peptides between dibasic residues. Trypsin  
normally exhibits high S1 specificity for Arg and Lys residues. However,  
the S1' specificity of trypsin is very broad, with only a slight  
preference for hydrophobic residues in P1'. Here, the authors replaced  
Lys-60 with Glu and Asp to introduce a high specificity for basic residues  
into the S1' site of trypsin. Both mutations caused a dramatic increase  
in S1' specificity for Arg and Lys as measured by acyl transfer reactions.  
In mutant K60E, the preference for Arg increased 70-fold, whereas the  
preference for P1'-Lys increased 12-fold. In contrast, the preferences  
for other P1' residues either decreased slightly or remained the same.  
Thus, K60E prefers P1'-Arg over most other P1' residues by 2 orders of  
magnitude. Similar results were obtained when P1' specificity was  
measured in peptide cleavage assays. K60D exhibited an S1' specificity  
profile very similar to that of K60E, although the P1'-Arg preference was  
reduced by a factor of 2.5. Mol. modeling studies suggested that the high  
S1' specificity for Arg in K60E may be due to the formation of a salt  
bridge between Glu-60 and P1'-Arg of the substrate.

OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>  
<--